PRODUCT MONOGRAPH

**PrNUVARING®**

etonogestrel/ethinyl estradiol slow release vaginal ring
(11.4 mg/2.6 mg) to deliver
120 mcg etonogestrel/15 mcg ethinyl estradiol per day

Contraceptive Vaginal Ring

FOR VAGINAL USE ONLY

Merck Canada Inc.
16750 route Transcanadienne
Kirkland, QC, Canada H9H 4M7
www.merck.ca

Date of Revision:
September 20, 2018

Submission Control No: 217697
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3
  SUMMARY PRODUCT INFORMATION ................................................................. 3
  INDICATIONS AND CLINICAL USE ................................................................. 3
  CONTRAINDICATIONS ......................................................................................... 3
  WARNINGS AND PRECAUTIONS ................................................................. 4
  ADVERSE REACTIONS ...................................................................................... 13
  DRUG INTERACTIONS ...................................................................................... 19
  DOSAGE AND ADMINISTRATION ................................................................. 27
  OVERDOSAGE ................................................................................................. 30
  ACTION AND CLINICAL PHARMACOLOGY .................................................. 30
  STORAGE AND STABILITY .............................................................................. 33
  SPECIAL HANDLING INSTRUCTIONS .......................................................... 33
  DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................... 33

PART II: SCIENTIFIC INFORMATION ................................................................. 34
  PHARMACEUTICAL INFORMATION ............................................................... 34
  CLINICAL TRIALS .......................................................................................... 36
  DETAILED PHARMACOLOGY ......................................................................... 43
  TOXICOLOGY .................................................................................................. 44
  REFERENCES .................................................................................................. 46

PART III: CONSUMER INFORMATION .......................................................... 50
NUVARING®
etonogestrel/ethinyl estradiol slow release vaginal ring

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form/Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaginal</td>
<td>Slow release vaginal ring, 11.4 mg etonogestrel/2.6 mg ethinyl estradiol (120 mcg etonogestrel/15 mcg ethinyl estradiol per day)</td>
<td>Ethylene vinylacetate copolymers For a complete listing see Dosage Forms, Composition and Packaging section</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

NuvaRing® (etonogestrel/ethinyl estradiol slow release vaginal ring) is indicated for:
- Conception control

Pediatrics (<18 years of age): The safety and efficacy of NuvaRing® in adolescents under the age of 18 have not been studied. Use of this product before menarche is not indicated.

CONTRAINDICATIONS

NuvaRing® should not be used in the presence of any of the conditions listed below. Should any of the conditions appear for the first time during the use of NuvaRing®, it should be removed immediately.
- Presence or history of venous thrombosis, with or without pulmonary embolism.
- Presence or history of arterial thrombosis (e.g., cerebrovascular accident, myocardial infarction) or prodromi of a thrombosis (e.g., angina pectoris or transient ischemic attack).
- Valvular heart disease with complications.
- Presence of a severe or multiple risk factor(s) for arterial or venous thrombosis (see WARNINGS AND PRECAUTIONS / Cardiovascular and Hematologic):
  - Severe hypertension (persistent values of ≥160/110 mmHg).
  - Known predisposition for venous or arterial thrombosis, with or without hereditary involvement such as Activated Protein C (APC-) resistance (including Factor V Leiden), antithrombin-III deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant).
  - Severe dyslipoproteinemia.
• Smoking, if over age 35.
• Diabetes mellitus with vascular involvement.
• Major surgery with prolonged immobilization (see WARNINGS AND PRECAUTIONS / General).
• History of migraine with focal neurological symptoms.
• Any ocular lesion arising from ophthalmic vascular disease, such as partial or complete loss of vision or defect in visual fields.
• Pancreatitis or a history thereof if associated with severe hypertriglyceridemia.
• Presence or history of severe hepatic disease as long as liver function values have not returned to normal.
• Use with the Hepatitis C virus combination drug regimen ombitasvir/paritaprevir/ritonavir with or without dasabuvir (see WARNINGS AND PRECAUTIONS/ Hepatic/Biliary/Pancreatic/Hepatitis C).
• Presence or history of liver tumors (benign or malignant).
• Known or suspected malignant conditions of the genital organs or the breasts, if sex steroid-influenced.
• Undiagnosed vaginal bleeding.
• Known or suspected pregnancy.
• Hypersensitivity to NuvaRing® or to any ingredient in the formulation or component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the Product Monograph.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including NuvaRing®, should not be used by women who are over 35 years of age and smoke (see WARNINGS AND PRECAUTIONS/ Cardiovascular section below).

Women should be counselled that NuvaRing® DOES NOT PROTECT against sexually transmitted infections (STIs) including HIV/AIDS. For protection against STIs, it is advisable to use latex or polyurethane condoms IN COMBINATION WITH NuvaRing®.

General

Discontinue medication at the earliest manifestation of:

A. Thromboembolic and Cardiovascular Disorders such as: Thrombophlebitis, pulmonary embolism, cerebrovascular disorders, myocardial ischemia, mesenteric thrombosis, and retinal thrombosis.
B. **Conditions which Predispose to Venous Stasis and to Vascular Thrombosis**, e.g., immobilization after accidents or confinement to bed during long-term illness. Other non-hormonal methods of contraception should be used until regular activities are resumed. For use of combination hormonal contraceptives when surgery is contemplated, see **Peri-Operative Considerations**.

C. **Visual Defects, Partial or Complete**.

D. **Papilledema, or Ophthalmic Vascular Lesions**.

E. **Severe Headache of Unknown Etiology or Worsening of Pre-existing Migraine Headache**.

F. **Increase in Epileptic Seizures**, see **DRUG INTERACTIONS / Table 4 Anticonvulsants**.

NuvaRing® and other contraceptives that contain both an estrogen and a progestin are called combination hormonal contraceptives. Most of the warnings below are based on data obtained from the oral route of administration.

The use of combination hormonal contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, although the risk of serious morbidity or mortality is small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly if associated with the presence of other risk factors such as hypertension, hyperlipidemias, obesity and diabetes. The excess risk of venous thromboembolism (VTE) is highest during the first year a woman ever uses a combined hormonal contraceptive. Other medical conditions which have been associated with adverse circulatory events include systemic lupus erythematosus, hemolytic uremic syndrome, chronic inflammatory bowel disease, (Crohn’s disease or ulcerative colitis), sickle cell disease, valvular heart disease, and atrial fibrillation.

The following conditions have been reported to occur or deteriorate with both pregnancy and CHC use, although a direct association with CHCs has not been firmly established: porphyria, systemic lupus erythematosus, hemolytic uremic syndrome, Sydenham’s chorea, herpes gestationis, and otosclerosis-related hearing loss.

If any of the conditions/risk factors mentioned below is present, the benefits of the use of NuvaRing® should be weighed against the possible risks for each individual woman and discussed with the woman before she decides to start using it. In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should contact her physician. The physician should then decide on whether NuvaRing® use should be discontinued.

**Carcinogenesis and Mutagenesis**

**Breast Cancer**

Increasing age and a strong family history are the most significant risk factors for the development of breast cancer. Other established risk factors include obesity, nulliparity and late age at first full-term pregnancy. The identified groups of women that may be at increased risk of developing breast cancer before menopause are long-term users (more than 8 years) of combination hormonal contraceptives (including NuvaRing®) and starters at early age. In a few women, the use of combination hormonal contraceptives (including NuvaRing®) may accelerate
the growth of an existing but undiagnosed breast cancer. Since any potential increased risk related to combination hormonal contraceptives (including NuvaRing®) use is small, there is no reason to change prescribing habits at present.

Women receiving combination hormonal contraceptives (including NuvaRing®) should be instructed in self-examination of their breasts. Their physicians should be notified whenever any masses are detected. A yearly clinical breast examination is also recommended because, if a breast cancer should develop, estrogen-containing drugs may cause a rapid progression.

**Cervical Cancer**
Persistent infection with the Human Papilloma Virus (HPV) is believed to be the most important risk factor for cervical cancer. Some epidemiological studies indicated that long-term use of combination oral contraceptives (COCs) may further contribute to this increased risk, but there continues to be controversy about the extent to which this finding may be confounded by other factors, e.g., cervical screening bias and sexual behaviour. It is unknown how this effect relates to NuvaRing®.

**Hepatocellular Carcinoma**
Studies have shown an increased risk of developing hepatocellular carcinoma in long term (>8 years) CHC users. However, the attributable risk of liver cancers in CHC users is less than one case per million users.

**Cardiovascular**

**Predisposing Factors for Coronary Artery Disease**
Cigarette smoking increases the risk of serious cardiovascular side effects and mortality. Combination hormonal contraceptives (including NuvaRing®), increase this risk, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, combination hormonal contraceptives, including NuvaRing®, should not be used by women who are over 35 years of age and smoke.

Convincing data are available to support an upper age limit of 35 years for combination hormonal contraceptive use in women who smoke.

Other women who are independently at high risk for cardiovascular disease include those with diabetes, hypertension, abnormal lipid profile, or a family history of these. Whether combination hormonal contraceptives, accentuate this risk is unclear.

In low-risk, non-smoking women of any age, the benefits of combination hormonal contraceptives use outweigh the possible cardiovascular risks associated with low-dose formulations.

Consequently, combination hormonal contraceptives may be prescribed for these women up to the age of menopause.
**Hypertension**
Patients with essential hypertension whose blood pressure is well-controlled may be prescribed combination hormonal contraceptives (including NuvaRing®) but only under close supervision. If a significant elevation of blood pressure in previously normotensive or hypertensive subjects occurs at any time during the administration of the drug, cessation of medication is necessary.

**Endocrine and Metabolism**

**Diabetes**
Current low-dose combination hormonal contraceptives (including NuvaRing®) exert minimal impact on glucose metabolism. Diabetic patients, or those with a family history of diabetes, should be observed closely to detect any worsening of carbohydrate metabolism. Patients predisposed to diabetes who can be kept under close supervision may be given combination hormonal contraceptives. Young diabetic patients whose disease is of recent origin, well-controlled, and not associated with hypertension or other signs of vascular disease such as ocular fundal changes, should be monitored more frequently while using combination hormonal contraceptives.

**Lipid and Other Metabolic Effects**
A small proportion of women will have adverse lipid changes while on combination hormonal contraceptives. Alternative contraception should be used in women with uncontrolled dyslipidemia (see also CONTRAINDICATIONS). Elevations of plasma triglycerides may lead to pancreatitis and other complications.

**Gastrointestinal**
Published epidemiological studies indicate a possible association of COC use and the development of Crohn’s disease and ulcerative colitis, although this has not been firmly established (2, 11, 20, 26, 33, 46).

**Genitourinary**
If a woman has any of the following conditions, she may not be able to insert NuvaRing® correctly or may in fact lose the ring: prolapse of the uterine cervix, cystocele, and/or rectocele, severe or chronic constipation.

During the use of NuvaRing®, women may occasionally experience vaginitis. There are no indications that the efficacy of NuvaRing® is affected by the treatment of vaginitis, nor that the use of NuvaRing® affects the treatment of vaginitis (see Drug-Drug Interactions).

**Vaginal Bleeding**
Persistent irregular vaginal bleeding requires assessment to exclude underlying pathology.

NuvaRing® may not be suitable for women with conditions that make the vagina more susceptible to vaginal irritation or ulceration. Very rarely, vaginal tissue may grow over the ring, necessitating removal by a healthcare provider. In some cases when the tissue had grown over the ring, removal was achieved by cutting the ring without incising the overlying vaginal tissue.
**Urethra**
Very rarely it has been reported that NuvaRing® was inadvertently inserted in the urethra and possibly ended up in the bladder. Healthcare providers should assess for incorrect placement of NuvaRing® in the urethra or bladder in those users presenting with persistent urinary symptoms and who are unable to locate the ring.

**Disconnected/Broken Ring**
On rare occasions, NuvaRing® has been reported to disconnect/break at the weld joint. Since the core of NuvaRing® is solid, its contents will remain intact and release of hormone is unlikely to occur. Vaginal injury associated with ring breakage has been reported. In the event of a disconnected/broken ring, expulsion (slipping out) is likely to occur (see “DRUG INTERACTIONS/Drug-Lifestyle Interactions/Expulsion”). If a woman discovers that her NuvaRing® has disconnected, she should discard the ring and replace it with a new ring.

**Fibroids**
Patients with fibroids (leiomyomata) should be carefully observed. Sudden enlargement, pain, or tenderness require discontinuation of the use of combination hormonal contraceptives (including NuvaRing®).

**Hematologic**
Compared to nonusers, the use of combined hormonal contraceptives (CHCs) has been associated with the increased risk of venous thrombosis (deep vein thrombosis and pulmonary embolism) and arterial thrombosis and associated complications. These events may sometimes be fatal.

As NuvaRing® is a contraceptive product with a vaginal route of administration delivering ethinyl estradiol and etonogestrel (the biological active metabolite of desogestrel) the following should be noted:

- Use of any CHCs carries an increased risk of venous thromboembolism (VTE), compared with no use. The excess risk of VTE is highest during the first year a woman ever uses a CHC. Data from a large, prospective cohort safety study of new users of various COCs suggest that this increased risk, as compared to that in non-COC users, is greatest during the first 6 months of COC use and is present after initially starting a COC or restarting (following a 4 week or greater pill-free interval) the same or a different COC. This increased risk of VTE in COC users is two to three-fold higher than for nonusers of COCs who are not pregnant and remains less than the risk of VTE associated with pregnancy and delivery.

  The risk of developing a VTE for women who use CHCs is 3-12 per 10,000 women-years compared to 1 - 5 per 10,000 women-years in non CHC users.
• Several epidemiological studies indicate that third-generation oral contraceptives, including those containing desogestrel (etonogestrel, the progestin component released by NuvaRing® is the biologically active metabolite of desogestrel) are associated with a higher risk of venous thromboembolism than certain second-generation oral contraceptives. These studies indicate an approximate 2-fold difference in risk, which corresponds to 1-2 cases of venous thromboembolism per 10,000 women-years of use. However, data from additional studies have not shown this difference in risk. It should be noted, however, that the incidence of venous thromboembolism in oral contraceptive users is rare.

• Known risk factors for VTE include smoking, obesity and family history of VTE, in addition to other factors that contraindicate use of COCs (see CONTRAINDICATIONS). VTE is fatal in 1-2% of cases.

• The increased risk of VTE with combined oral contraceptives gradually disappears after COC use is discontinued.

Three epidemiological studies have examined the risk of VTE with NuvaRing® versus combined oral contraceptives. A large, sponsor-funded, prospective cohort study has shown that the frequency of VTE diagnosis was estimated at about 8.3 events per 10,000 woman-years (WY) in new users of NuvaRing®, compared to 7.8 events per 10,000 WY in new users of levonorgestrel (LNG)-containing COC. The study also reported a VTE incidence of 5.0 events per 10,000 WY in non-pregnant, non-COC users and 29.0 events per 10,000 WY in pregnant or postpartum women(6).

A retrospective cohort study conducted in the United States showed a VTE incidence rate for all users (including new users and continuous users) of NuvaRing® of 11.91 events per 10,000 WY and for all users of a LNG-containing COC of 6.64 events per 10,000 WY(8). The corresponding incidence rates for new users in the same study were 11.35 and 9.21 events per 10,000 WY for NuvaRing® and LNG, respectively(27).

A second retrospective cohort study using data from the Denmark National Registry showed a VTE incidence for all users of NuvaRing® of 7.8 events per 10,000 WY and for all users of a LNG-containing COC of 6.2 events per 10,000 WY. A new user analysis was not conducted in this study(18).

Epidemiological studies have inherent methodological issues making the interpretation of their results complex (6, 8, 18, 27). Prescribers should consider the benefits and risks for specific women with respect to VTE risk given the results of epidemiological studies of both new and continuous users of CHCs (see ADVERSE EVENTS, Post-Market Epidemiological Cohort Studies).

Women using combined hormonal contraceptives (CHCs) should be advised to contact their physician in case of possible symptoms of thrombosis. In case of suspected or confirmed thrombosis, CHC use should be discontinued. Adequate contraception should be initiated because of the teratogenicity of anti-coagulant therapy (coumarins).
**Hepatic/Biliary/Pancreatic**

**Jaundice**
Patients who have had jaundice including a history of cholestatic jaundice during pregnancy should be given combination hormonal contraceptives (including NuvaRing®) with great care and under close observation.

The development of severe generalized pruritus or icterus requires that the medication be withdrawn until the problem is resolved.

If the jaundice should prove to be cholestatic in type, the use of combination hormonal contraceptives should not be resumed. In patients taking combination hormonal contraceptives, changes in the composition of the bile may occur and an increased incidence of gallstones has been reported.

**Hepatic Nodules**
Hepatic nodules (adenoma and focal nodular hyperplasia) have been reported, particularly in long-term users of combination hormonal contraceptives. Although these lesions are extremely rare, they have caused fatal intra-abdominal hemorrhage and should be considered in women presenting with an abdominal mass, acute abdominal pain, or evidence of intra-abdominal bleeding.

**Hepatitis C**
During clinical trials with the HCV combination drug regimen ombitasvir/paritaprevir/ritonavir with and without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN) were significantly more frequent in women using ethinylestradiol-containing medications such as CHCs. NuvaRing® must be discontinued prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir with or without dasabuvir (see CONTRAINDICATIONS and DRUG INTERACTIONS). NuvaRing® can be restarted approximately 2 weeks following completion of treatment with the HCV combination drug regimen.

**Immune**

**Angioedema and anaphylaxis**
Exogenous estrogens may induce or exacerbate symptoms of angioedema, in particular in women with hereditary angioedema.

Hypersensitivity reactions of angioedema and anaphylaxis have been reported during use of NuvaRing®.

If angioedema and/or anaphylaxis are suspected, NuvaRing® should be discontinued and appropriate treatment administered.

**Neurologic**

**Migraine and Headache**
The onset or exacerbation of migraine or the development of headache of a new pattern which is recurrent, persistent or severe, requires discontinuation of combination hormonal contraceptives (including NuvaRing®) and evaluation of the cause. Women with migraine headaches who take combination hormonal contraceptives may be at increased risk of stroke (see CONTRAINDICATIONS).
**Ophthalmologic**

**Ocular Disease**

Patients who are pregnant or are using combination hormonal contraceptives (including NuvaRing®), may experience corneal edema that may cause visual disturbances and changes in tolerance to contact lenses, especially of the rigid type. Soft contact lenses usually do not cause disturbances. If visual changes or alterations in tolerance to contact lenses occur, temporary or permanent cessation of wear may be advised.

**Ocular Lesions**

There have been clinical reports of retinal thrombosis associated with the use of combination hormonal contraceptives. Combination hormonal contraceptives (including NuvaRing®) should be discontinued if there is unexplained transient, partial or complete loss of vision; onset of proptosis or diplopia; papilledema or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately.

**Peri-Operative Considerations**

**Thromboembolic Complications – Post-surgery**

There is an increased risk of post-surgery thromboembolic complications in combination hormonal contraceptive (including NuvaRing®) users, after major surgery. If feasible, combination hormonal contraceptives should be discontinued and an alternative method substituted at least one month prior to MAJOR elective surgery. Combination hormonal contraceptives should not be resumed until the first menstrual period after hospital discharge following surgery.

**Psychiatric**

**Emotional Disorders**

Patients with a history of emotional disturbances, especially the depressive type, may be more prone to have a recurrence of depression while using combination hormonal contraceptives (including NuvaRing®). In cases of a serious recurrence, a trial of an alternate method of contraception should be made which may help to clarify the possible relationship. Women with premenstrual syndrome (PMS) may have a varied response to combination hormonal contraceptives, ranging from symptomatic improvement to worsening of the condition.

**Sexual Function/Reproduction**

**Return to Fertility**

After discontinuing combination hormonal contraceptive (including NuvaRing®) therapy, the patient should delay pregnancy until at least one normal spontaneous cycle has occurred in order to date the pregnancy. An alternate contraceptive method should be used during this time.

**Amenorrhea**

In some women, withdrawal bleeding may not occur during the ring-free interval. If NuvaRing® has been used according to directions; it is unlikely that the woman is pregnant. However, if NuvaRing® has not been used according to directions prior to the first missed withdrawal bleed, or if two withdrawal bleeds are missed, pregnancy must be ruled out before NuvaRing® use is continued.
Women having a history of oligomenorrhea, secondary amenorrhea, or irregular cycles may remain anovulatory or become amenorrheic following discontinuation of estrogen-progestin combination therapy.

Amenorrhea, especially if associated with breast secretion, that continues for six months or more after withdrawal, warrants a careful assessment of hypothalamic-pituitary function.

**Reduced Efficacy**
The efficacy of NuvaRing® may be reduced in the event of non-compliance, or when concomitant medications that decrease the plasma concentration of ethinyl estradiol and/or etonogestrel are used (see DOSAGE AND ADMINISTRATION and DRUG INTERACTIONS).

**Skin**
Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation while using NuvaRing®.

**Special Populations**

**Pregnant Women:** Combination hormonal contraceptives (including NuvaRing®) should not be used by pregnant women. However, if conception accidentally occurs while using combination hormonal contraceptives, there is no conclusive evidence that the estrogen and progestin contained in combination hormonal contraceptives will damage the developing child.

The extent of exposure in pregnancy during clinical trials: Very Limited: individual cases only

**Nursing Women:** The effects of NuvaRing® in nursing mothers have not been evaluated and are unknown. In breastfeeding women, the use of combination hormonal contraceptives results in the hormonal components being excreted in breast milk and may reduce its quantity and quality. If the use of combination hormonal contraceptives is initiated after the establishment of lactation, there does not appear to be any effect on the quantity and quality of the milk. There is no evidence that low-dose combination hormonal contraceptives are harmful to the nursing infant. However, women who are breast feeding should be advised not to use CHCs (including NuvaRing®) but to use other forms of contraception until the child is weaned.

**Risk to the Partner**
The extent and possible pharmacological role of exposure of male sexual partners to ethinyl estradiol and etonogestrel through absorption through the penis have not been determined.

**Monitoring and Laboratory Tests**

**Physical Examination and Follow-up**
Before combination hormonal contraceptives (including NuvaRing®) are used, a thorough history and physical examination should be performed, including a blood pressure determination. Breasts, liver, extremities and pelvic organs should be examined. A Papanicolaou smear should be taken if the patient has been sexually active.
The first follow-up visit should be done three months after combination hormonal contraceptives are prescribed. Thereafter, examinations should be performed at least once a year or more frequently if indicated. At each annual visit, examination should include those procedures that were done at the initial visit as outlined above or per recommendations of the Canadian Task Force on the Periodic Health Examination.

**ADVERSE REACTIONS**

**Adverse Drug Reaction Overview**
An increased risk of the following serious adverse reactions has been associated with the use of combination hormonal contraceptives (including NuvaRing®):
- Arterial and venous thromboembolism
- Thrombophlebitis
- Pulmonary embolism
- Mesenteric thrombosis
- Neuro-ocular lesions, e.g., retinal thrombosis
- Myocardial infarction
- Cerebral thrombosis
- Cerebral hemorrhage
- Hypertension
- Benign and malignant hepatic tumors
- Gallbladder disease
- Congenital anomalies

The following adverse reactions also have been reported in patients receiving combination hormonal contraceptives:

Nausea and vomiting constitute the most common adverse reactions and occur in approximately 10% of patients during the first cycle.

Other reactions, observed with a frequency of <10%, include:
- Gastrointestinal symptoms (such as abdominal cramps and bloating)
- Breakthrough bleeding
- Spotting
- Change in menstrual flow
- Dysmenorrhea
- Amenorrhea during and after treatment
- Temporary infertility after discontinuance of treatment
- Edema
- Chloasma or melasma which may persist
- Breast changes: tenderness, enlargement, and secretion
- Change in weight (increase [5%] or decrease [0.1%])
- Endocervical hyperplasias
- Possible diminution in lactation when given immediately post-partum
- Cholestatic jaundice
- Migraine
- Increase in size of uterine leiomyomata
- Rash (allergic)
- Mental depression
- Reduced tolerance to carbohydrates
- Vaginal candidiasis
- Premenstrual-like syndrome
- Intolerance to contact lenses
- Change in corneal curvature (steepening)
- Cataracts
- Optic neuritis
- Retinal thrombosis
- Changes in libido
- Chorea
- Changes in appetite
- Cystitis-like syndrome
- Rhinitis
- Headache
- Nervousness
- Dizziness
- Hirsutism
- Loss of scalp hair
- Erythema multiforme
- Erythema nodosum
- Hemorrhagic eruption
- Vaginitis
- Porphyria
- Impaired renal function
- Raynaud’s phenomenon
- Auditory disturbances
- Hemolytic uremic syndrome
- Pancreatitis

**Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

The most common treatment-related AEs seen in the two pivotal clinical studies were headache, vaginitis, and leukorrhea (Table 1). These adverse events as well as the incidence of acne, breast tenderness, and nausea which are typical of contraceptives were low.
Table 1 – Treatment related adverse events occurring in ≥1% of subjects in all pivotal clinical studies

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Adverse Event</th>
<th>n*</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin and Appendages Disorders</td>
<td>Acne</td>
<td>46</td>
<td>2.0</td>
</tr>
<tr>
<td>Central &amp; Peripheral Nervous System Disorders</td>
<td>Headache</td>
<td>135</td>
<td>5.8</td>
</tr>
<tr>
<td></td>
<td>Migraine</td>
<td>24</td>
<td>1.0</td>
</tr>
<tr>
<td>Psychiatric Disorders</td>
<td>Emotional lability</td>
<td>64</td>
<td>2.8</td>
</tr>
<tr>
<td></td>
<td>Libido decreased</td>
<td>31</td>
<td>1.3</td>
</tr>
<tr>
<td></td>
<td>Depression</td>
<td>33</td>
<td>1.4</td>
</tr>
<tr>
<td>Gastrointestinal System Disorders</td>
<td>Nausea</td>
<td>74</td>
<td>3.2</td>
</tr>
<tr>
<td></td>
<td>Abdominal pain</td>
<td>24</td>
<td>1.0</td>
</tr>
<tr>
<td>Metabolic and Nutritional Disorders</td>
<td>Weight increase</td>
<td>93</td>
<td>4.0</td>
</tr>
<tr>
<td>Reproductive Disorders, Female</td>
<td>Vaginitis</td>
<td>130</td>
<td>5.6</td>
</tr>
<tr>
<td></td>
<td>Leukorrhea</td>
<td>111</td>
<td>4.8</td>
</tr>
<tr>
<td></td>
<td>Device related problems</td>
<td>103</td>
<td>4.4</td>
</tr>
<tr>
<td></td>
<td>Breast pain (female)</td>
<td>61</td>
<td>2.6</td>
</tr>
<tr>
<td></td>
<td>Dysmenorrhea</td>
<td>60</td>
<td>2.6</td>
</tr>
<tr>
<td></td>
<td>Vaginal discomfort</td>
<td>56</td>
<td>2.4</td>
</tr>
<tr>
<td></td>
<td>Abdominal pain (gynecological)</td>
<td>36</td>
<td>1.6</td>
</tr>
</tbody>
</table>

*Total n=2,322 subjects

Cervical cytology was assessed in 2,039 women during treatment with NuvaRing®. For the majority of subjects, the cervical Pap smear result was Pap I at screening and at last assessment. A small number of subjects had a change from normal (Pap smear result of I, IIa, or IIb) at screening to a Pap result of III or IIIa at last assessment (n=33, 1.3%). Clinically relevant shifts of particular note occurred for 7 subjects with a Pap result of I at screening to a Pap result of IIIb/IV (high-grade SIL) at last assessment. In summary, changes to abnormal cervical cytology occurred in a low percentage of the subjects.

In the comparative metabolic studies, the incidence of adverse events was similar for the NuvaRing® and LNG/EE OC group (57.9% and 54.0%, respectively). The incidence of drug-related AEs was higher in the NuvaRing® group than in the LNG/EE OC group (33.9% and 24.6%, respectively), partly due to the AEs device-related events and vaginal discomfort, which were only reported in the NuvaRing® group. Medical and gynecologic examinations performed before and after the studies showed no clinically relevant changes in either group. Heart rate and blood pressure did not change significantly from baseline in either group. Overall, the tolerability of both contraceptives was good (Table 2).
Table 2 – Adverse Events (at Least Possibly Related) Occurring in ≥2% – Metabolic Comparative Studies (NuvaRing® n=121; COC n=126)

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>NuvaRing® n (%)</th>
<th>COC n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acne</td>
<td>2 (1.7)</td>
<td>3 (2.4)</td>
</tr>
<tr>
<td>Breast tenderness</td>
<td>5 (4.1)</td>
<td>5 (4.0)</td>
</tr>
<tr>
<td>Decreased libido</td>
<td>10 (8.3)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Depression</td>
<td>0 (0.0)</td>
<td>6 (4.8)</td>
</tr>
<tr>
<td>Device-related events¹</td>
<td>3 (2.5)</td>
<td>NA²</td>
</tr>
<tr>
<td>Headache</td>
<td>4 (3.3)</td>
<td>3 (2.4)</td>
</tr>
<tr>
<td>Leukorrhea</td>
<td>3 (2.5)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Nausea</td>
<td>6 (5.0)</td>
<td>4 (3.2)</td>
</tr>
<tr>
<td>Nervousness</td>
<td>3 (2.5)</td>
<td>2 (1.6)</td>
</tr>
<tr>
<td>Weight increase</td>
<td>4 (3.3)</td>
<td>2 (1.6)</td>
</tr>
<tr>
<td>Vaginal discomfort</td>
<td>3 (2.5)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Vaginitis</td>
<td>5 (4.1)</td>
<td>2 (1.6)</td>
</tr>
</tbody>
</table>

¹Comprising foreign body feeling, coital problems, and expulsion (WHO terms)
²NA = Not applicable

Less Common Clinical Trial Adverse Drug Reactions (<1% at least possibly related)

Other rare adverse events which were observed in clinical trials were as follows:

- **Skin & appendages** – alopecia, dermatitis fungal, eczema, photosensitivity reaction, pigmentation abnormal, pruritus, pruritus genital, rash, rash maculo-papular, seborrhea, skin discoloration, skin disorder, skin dry
- **Musculo-skeletal system disorders** – arthralgia, muscle weakness
- **Central & peripheral nervous system disorder** – aphasia, cramps legs, dizziness, dysesthesia, hypoesthesia, migraine aggravated, paraesthesia, vertigo
- **Vision disorders** – conjunctivitis, vision abnormal
- **Psychiatric disorders** – aggressive reaction, agitation, anorexia, anxiety, apathy, appetite increased, concentration impaired, depression aggravated, hallucination, insomnia, libido increased, nervousness
- **Gastrointestinal system disorders** – anus disorder, change in bowel habits, colitis ulcerative aggravated, constipation, diarrhea, dyspepsia, flatulence, hemorrhoids, rectal disorder, tenesmus, vomiting
- **Liver and biliary system disorders** – cholelithiasis, SGOT increased
- **Metabolic and nutritional disorders** – dehydration, hypercholesterolemia, hypertriglyceridemia, oedema generalised, xerophthalmia
- **Endocrine disorders** – estrogens increased, glucocorticoids increased, hypothyroidism
- **Cardiovascular disorders, general** – hypertension, hypotension, oedema dependent
- **Heart rate and rhythm disorders** – palpitation
Vascular (extracardiac) disorders – thrombophlebitis, thrombophlebitis deep, thrombophlebitis superficial,
Respiratory system disorders – asthma, dyspnea, rhinitis
Red blood cell disorders – anemia
Platelet, bleeding & clotting disorders – hematoma, purpura
Urinary system disorders – bladder discomfort, cystitis, dysuria, micturition frequency, micturition urgency, strangury, urinary incontinence, urinary tract infection
Reproductive disorders, male – device-related problems, penis disorders including pain, rash, bruises and abrasions
Reproductive disorders, female – amenorrhea, bleeding irregularity, breast enlargement, cervical dysplasia, cervicitis, cervix lesion, ectopy, endometritis, lactation nonpuerperal, mastitis, ovarian disorder, ovarian mass, ovarian pain, pelvic inflammation, premenstrual tension, uterine disorder nos, vulva discomfort, vulva disorder
Neoplasm – breast fibroadenosis, breast neoplasm benign female, cervical smear test positive, cervical uterine polyp, hemangioma acquired, ovarian cyst, uterine fibroid, vaginal neoplasm benign
Body as a whole – abdomen enlarged, allergic reaction, asthenia, back pain, chest pain, fatigue, hot flushes, influenza-like symptoms, leg pain, malaise, oedema, oedema peripheral, pain, temperature-changed sensation
Application site disorders – skin nodule
Resistance mechanism disorders – infection viral
Secondary terms – cervical smear test PAP II
Undefined system-organ class – Cervical smear PAP II

Post-Market Adverse Drug Reactions
In general, post-marketing data are in agreement with the expectations and conclusions based on the clinical development program, except for some unanticipated reports related to disconnected rings (<0.005%). Vaginal injury associated with ring breakage has also been reported (see WARNINGS AND PRECAUTIONS / Genitourinary). In addition, hypersensitivity reactions including angioedema and anaphylaxis have been reported.

Post-Market Epidemiological Cohort Studies
NuvaRing® users had a risk of VTE similar to COC users (see table below for adjusted hazard ratios). A large prospective, observational study, the Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing® (TASC), investigated the risk of VTE for new users of NuvaRing® and COCs in a population that is representative of routine clinical users. The women were followed for 24 to 48 months. The results showed a similar risk of VTE among NuvaRing® users (VTE incidence 8.3 per 10,000 WY) and women using COCs (VTE incidence 9.2 per 10,000 WY). For women using levonorgestrel (LNG)-containing COCs, VTE incidence was 7.8 per 10,000 WY. Incidence of VTE was 5.0 per 10,000 woman-years in non-pregnant, non-COC and 29.0 per 10,000 woman-years in pregnant or postpartum women(6).

A retrospective cohort study using data from 4 health plans in the US ("FDA-funded study") showed a VTE incidence rate for all users (including new users and continuous users) of NuvaRing® of 11.91 events per 10,000 WY and for all users of a LNG-containing COC of 6.64 events per 10,000 WY(8). The corresponding incidence rates for new users in the same study were 11.35 and 9.21 events per 10,000 WY for NuvaRing® and LNG, respectively(27).
A second retrospective cohort study using data from the Denmark National Registry showed a VTE incidence for all users of NuvaRing® of 7.8 events per 10,000 WY and for all users of a LNG-containing COC of 6.2 events per 10,000 WY. A new user analysis was not conducted in this study.(18)

<table>
<thead>
<tr>
<th>Epidemiologic Study</th>
<th>Comparator Product(s)</th>
<th>Hazard Ratios (HR) (95% CI) New Users</th>
<th>Hazard Ratios (HR) or Rate Ratio (RR) (95% CI) All Users</th>
</tr>
</thead>
<tbody>
<tr>
<td>TASC(6)</td>
<td>All COCs available during the course of the study *</td>
<td>HR†: 0.8 (0.5-1.5)</td>
<td>n/a</td>
</tr>
<tr>
<td></td>
<td>COCs available excluding DSG-, GSD-, DRSP- containing OCs</td>
<td>HR†: 0.9 (0.4-2.0)</td>
<td></td>
</tr>
<tr>
<td>FDA-funded study(8)</td>
<td>COCs available during the course of the study§</td>
<td>HR¶: 1.09 (0.55-2.16)</td>
<td>HR¶: 1.56 (1.02-2.37)</td>
</tr>
<tr>
<td></td>
<td>LNG/0.03 mg ethinyl estradiol</td>
<td>HR¶: 0.96 (0.47-1.95)</td>
<td>HR¶: 1.28 (0.83-1.99)</td>
</tr>
<tr>
<td>Danish Study(18)</td>
<td>LNG/0.03-0.04 mg ethinyl estradiol</td>
<td>n/a</td>
<td>RR¥: 1.9 (1.34-2.7)</td>
</tr>
</tbody>
</table>

* Includes low-dose COCs containing the following progestins: chlormadinone acetate, cyproterone acetate, desogestrel, dienogest, drospirenone, ethynodiol diacetate, gestodene, levonorgestrel, norethindrone, norgestimate, or norgestrel.
† adjusted for age, BMI, duration of use, VTE history
§ includes low-dose COCs containing the following progestins: norgestimate, norethindrone, or levonorgestrel
¶ adjusted for age, site, year of entry into study
¥ adjusted for age, calendar year and education
DRUG INTERACTIONS

Overview
Note: The prescribing information of concomitant medications should be consulted to identify potential interactions.

The concurrent administration of combination hormonal contraceptives (including NuvaRing®) with other medicinal products may result in an altered response to either agent (Tables 4 and 5). Reduced effectiveness of combination hormonal contraceptives (including NuvaRing®), is more likely with the low-dose formulations. This could result in unintended pregnancy or breakthrough bleeding. It is important to ascertain all drugs that a patient is taking, both prescription and non-prescription, before combination hormonal contraceptives (including NuvaRing®) are prescribed.

Hepatic metabolism: Interactions can occur with medicinal or herbal products that induce microsomal enzymes, specifically cytochrome P450 enzymes (CYP), which can result in increased clearance reducing plasma concentrations of sex hormones and may decrease the effectiveness of combination hormonal contraceptives, including NuvaRing®. These products are identified in Drug-Drug Interactions and Drug-Herb Interactions with an (*). Enzyme induction can occur after a few days of treatment. Maximum enzyme induction is generally observed within a few weeks. After drug therapy is discontinued, enzyme induction can last for about 28 days. For women on long-term therapy with enzyme-inducing medicinal products, an alternative method of contraception unaffected by enzyme-inducing medicinal products should be considered.

Drug-Drug Interactions
Interactions between contraceptive steroids and other drugs have been reported in the literature.

Table 4 – Drugs Which May Decrease the Efficacy of Combination Hormonal Contraceptives (CHC)

<table>
<thead>
<tr>
<th>Class of Compound</th>
<th>Drug</th>
<th>Proposed Mechanism</th>
<th>Suggested Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antacids</td>
<td></td>
<td>Decreased intestinal absorption of progestins.</td>
<td></td>
</tr>
<tr>
<td>Antibiotics</td>
<td>Chloramphenicol, Neomycin, Nitrofurantoin, Sulfonamides</td>
<td>Induction of hepatic microsomal enzymes. Also disturbance of enterohepatic circulation.</td>
<td>For short course, use a barrier contraceptive method in addition to Nuvaring® during administration and for 28 days after discontinuation. NuvaRing® should not be used with a diaphragm, cervical cap or female condom. For long course of enzyme inducing drugs, use another method of contraception unaffected by enzyme induction.</td>
</tr>
<tr>
<td></td>
<td>Troleandomycin</td>
<td>May retard metabolism of CHC increasing the risk of cholestatic jaundice.</td>
<td></td>
</tr>
<tr>
<td>Class of Compound</td>
<td>Drug</td>
<td>Proposed Mechanism</td>
<td>Suggested Management</td>
</tr>
<tr>
<td>-------------------</td>
<td>-----------------------</td>
<td>--------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Rifabutin(*)</td>
<td>Increased metabolism of progestins.</td>
<td>Use another method.</td>
</tr>
<tr>
<td></td>
<td>Rifampicin(*)</td>
<td>Suspected acceleration of estrogen metabolism.</td>
<td>For short course, use a barrier contraceptive method in addition to NuvaRing® during administration and for 28 days after discontinuation. NuvaRing® should not be used with a diaphragm, cervical cap or female condom. For long course of enzyme inducing drugs, use another method of contraception unaffected by enzyme induction.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carbamazepine(*)</td>
<td>Induction of hepatic microsomal enzymes:</td>
<td>For short course, use a barrier contraceptive method in addition to NuvaRing® during administration and for 28 days after discontinuation. NuvaRing® should not be used with a diaphragm, cervical cap or female condom. For long course of enzyme inducing drugs, use another method of contraception unaffected by enzyme induction.</td>
</tr>
<tr>
<td></td>
<td>Felbamate(*)</td>
<td>Rapid metabolism of estrogen and increased binding of progestin and ethinyl estradiol to SHBG.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lamotrigine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oxicarbazepine(*)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phenobarbital(*)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phenytoin(*)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Primidone(*)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topiramate(*)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Griseofulvin(*)</td>
<td>Stimulation of hepatic metabolism of contraceptive steroids may occur.</td>
<td>Use another method. For short course, use a barrier contraceptive method in addition to NuvaRing® during administration and for 28 days after discontinuation. NuvaRing® should not be used with a diaphragm, cervical cap or female condom. For long course of enzyme inducing drug, use another method of contraception unaffected by enzyme induction.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Boceprevir</td>
<td>HCV and HIV combination therapy may alter clearance of the sex hormones; decreased, increased or no change in the plasma concentrations of the progestin or estrogen component.</td>
<td>For short course, use a barrier contraceptive method in addition to NuvaRing® during administration and for 28 days after discontinuation. NuvaRing® should not be used with a diaphragm, cervical cap or female condom. For long course of enzyme inducing drug, use another method of contraception unaffected by enzyme induction.</td>
</tr>
<tr>
<td></td>
<td>Telaprevir</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nelfinavir(*)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ritonavir(*)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nevirapine</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Efavirenz(*)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Barbiturates</td>
<td>Induction of hepatic microsomal enzymes.</td>
<td>For short course, use a barrier contraceptive method in addition to NuvaRing® during administration and for 28 days after discontinuation. NuvaRing® should not be used with a diaphragm, cervical cap or female condom. For long course of enzyme inducing drugs, use another method of contraception unaffected by enzyme induction.</td>
</tr>
<tr>
<td></td>
<td>Glutethimide(*)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Meprobamate(*)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Pulmonary arterial hypertension Drugs

<table>
<thead>
<tr>
<th>Class of Compound</th>
<th>Drug</th>
<th>Proposed Mechanism</th>
<th>Suggested Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bosentan(*)</td>
<td>Induction of hepatic microsomal enzymes</td>
<td>For short course, use a barrier contraceptive method in addition to NuvaRing® during administration and for 28 days after discontinuation. NuvaRing® should not be used with a diaphragm, cervical cap or female condom. For long course of enzyme inducing drugs, use another method of contraception unaffected by enzyme induction.</td>
<td></td>
</tr>
</tbody>
</table>

Other Drugs

<table>
<thead>
<tr>
<th>Class of Compound</th>
<th>Drug</th>
<th>Modification of Other Drug Action</th>
<th>Suggested Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analgesics</td>
<td>Reduced contraceptive efficacy has been reported. Remains to be confirmed.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antihistamines</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antimigraine preparations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenylbutazone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin E</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Hormonal contraceptives may interfere with the metabolism of other drugs. Accordingly, plasma and tissue concentrations may either increase (eg, cyclosporine) or decrease (eg, lamotrigine).

If concomitant drug administration runs beyond the 3 weeks of a ring cycle, the next ring should be inserted immediately, without having the usual ring-free interval.

Table 5 – Modification of Other Drug Action by Combined Hormone Contraceptives

<table>
<thead>
<tr>
<th>Class of Compound</th>
<th>Drug</th>
<th>Modification of Other Drug Action</th>
<th>Suggested Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol</td>
<td>Possible increased levels of ethanol or acetaldehyde.</td>
<td>Use with caution.</td>
<td></td>
</tr>
<tr>
<td>Alpha-II Adrenoreceptor Agents</td>
<td>Clonidine</td>
<td>Sedation effect increased.</td>
<td>Use with caution.</td>
</tr>
<tr>
<td>Anticoagulants</td>
<td>All</td>
<td>CHCs increase clotting factors, decrease efficacy. However CHC may potentiate action in some patients.</td>
<td>Use another method.</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>All</td>
<td>Estrogens may increase risk of seizures.</td>
<td>Use another method.</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>Decreased lamotrigine levels may lead to breakthrough seizures</td>
<td>Use another method.</td>
<td></td>
</tr>
<tr>
<td>Antidiabetic Drugs</td>
<td>Oral Hypoglycemics and Insulin</td>
<td>CHCs may impair glucose tolerance and increase blood glucose.</td>
<td>Use low dose estrogen and progestin CHC or another method. Monitor blood glucose.</td>
</tr>
<tr>
<td>Antihypertensive Agents</td>
<td>Guanethidine and Methyldopa</td>
<td>Estrogen component cause sodium retention, progestin has no effect.</td>
<td>Use low estrogen CHC or use another method.</td>
</tr>
<tr>
<td>Class of Compound</td>
<td>Drug</td>
<td>Modification of Other Drug Action</td>
<td>Suggested Management</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------------------------------------</td>
<td>--------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Antipyretics</td>
<td>Acetaminophen</td>
<td>Increased metabolism and renal clearance.</td>
<td>Dose of drug may have to be increased.</td>
</tr>
<tr>
<td></td>
<td>Antipyridine</td>
<td>Impaired metabolism.</td>
<td>Decrease dose of drug.</td>
</tr>
<tr>
<td></td>
<td>ASA</td>
<td>Effects of ASA may be decreased by the short-term use of CHCs.</td>
<td>Patients on chronic ASA therapy may require an increase in ASA dosage.</td>
</tr>
<tr>
<td></td>
<td>Aminocaproic Acid</td>
<td>Theoretically, a hypercoagulable state may occur because CHCs augment clotting factors.</td>
<td>Avoid concomitant use.</td>
</tr>
<tr>
<td>Betamimetic Agents</td>
<td>Isoproterenol</td>
<td>Estrogen causes decreased response to these drugs.</td>
<td>Adjust dose of drug as necessary. Discontinuing CHCs can result in excessive drug activity.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Caffeine</td>
<td>The actions of caffeine may be enhanced as CHCs may impair the hepatic metabolism of caffeine.</td>
<td>Use with caution.</td>
</tr>
<tr>
<td></td>
<td>Cholesterol Lowering Agents</td>
<td>CHCs may increase the clearance of clofibrate leading to decreased level of clofibrate.</td>
<td>Use with caution.</td>
</tr>
<tr>
<td></td>
<td>Clofibrate</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Corticosteroids</td>
<td>Markedly increased serum levels.</td>
<td>Possible need for decrease in dose.</td>
</tr>
<tr>
<td></td>
<td>Prednisone</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cyclosporine</td>
<td>May lead to an increase in cyclosporine levels and hepatotoxicity.</td>
<td>Monitor hepatic function. The cyclosporine dose may have to be decreased.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Folic Acid</td>
<td>CHCs have been reported to impair folate metabolism.</td>
<td>Use combination with caution.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Meperidine</td>
<td>Possible increased analgesia and CNS depression due to decreased metabolism of meperidine.</td>
<td>Use combination with caution.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phenothiazine Tranquilizers</td>
<td>Estrogen potentiates the hyperprolactinemia effect of these drugs.</td>
<td>Use other drugs or lower dose CHCs. If galactorrhea or hyperprolactinemia, occurs use other method.</td>
</tr>
<tr>
<td></td>
<td>All Phenothiazines, Reserpine and similar drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sedatives and Hypnotics</td>
<td>Increased effect (increased metabolism).</td>
<td>Use with caution.</td>
</tr>
<tr>
<td></td>
<td>Chlordiazepoxide, Lorazepam, Oxazepam, Diazepam</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Theophylline</td>
<td>Decreased oxidation, leading to possible toxicity.</td>
<td>Use with caution. Monitor theophylline levels.</td>
</tr>
<tr>
<td>Class of Compound</td>
<td>Drug</td>
<td>Modification of Other Drug Action</td>
<td>Suggested Management</td>
</tr>
<tr>
<td>------------------------</td>
<td>-------------------------------</td>
<td>-----------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Tricyclic Antidepressants</td>
<td>Clomipramine (possibly others)</td>
<td>Increased side effects: i.e., depression.</td>
<td>Use with caution.</td>
</tr>
<tr>
<td>Vitamin B₁₂</td>
<td></td>
<td>CHCs have been reported to reduce serum levels of Vitamin B₁₂.</td>
<td></td>
</tr>
</tbody>
</table>

**Protease and Transcriptase Inhibitors**

When co-administered with hormonal contraceptives, many combinations of HIV protease inhibitors (e.g., nelfinavir) and non-nucleoside reverse transcriptase inhibitors (e.g., nevirapine), and/or combinations with Hepatitis C virus (HCV) medicinal products (e.g., boceprevir, telaprevir) can increase or decrease plasma concentrations of estrogens or progestins, including etonogestrel. The efficacy and safety of oral contraceptive products may be affected; it is unknown whether this applies to NuvaRing®. Healthcare providers should refer to the label of the individual anti-HIV/HCV protease inhibitors for further drug-drug interaction information.

During clinical trials with the HCV combination drug regimen ombitasvir/paritaprevir/ritonavir with and without dasabuvir, ALT elevations greater than 5 times the upper limit of normal (ULN) were significantly more frequent in women using ethinylestradiol-containing medications such as CHCs. NuvaRing® must be discontinued prior to starting therapy with the combination drug regimen ombitasvir/paritaprevir/ritonavir with or without dasabuvir (see **CONTRAINDICATIONS** and **WARNINGS AND PRECAUTIONS/Hepatic/Biliary/Pancreatic/Hepatitis C**). NuvaRing® can be restarted approximately 2 weeks following completion of treatment with the HCV combination drug regimen.

**Strong and moderate CYP3A4 Inhibitors**

Concomitant administration of strong (e.g., ketoconazole, itraconazole, clarithromycin) or moderate (e.g., fluconazole, diltiazem, erythromycin) CYP 3A4 inhibitors may increase the serum concentrations of estrogens or progestins, including etonogestrel.

**Antibiotics**

The serum concentrations of etonogestrel and ethinyl estradiol were not affected by concomitant administration of oral amoxicillin or doxycycline in standard dosages during 10 days of antibiotic treatment. The effects of other antibiotics on etonogestrel or ethinylestradiol concentrations have not been evaluated.

**Nonoxynol-9 spermicide gel and Miconazole nitrate capsule/suppository**

The single dose of 100 mg vaginally administered, water-based nonoxyl-9 gel did not affect the serum concentrations of etonogestrel or ethinyl estradiol.

The single dose of 1,200 mg vaginally-administered, oil-based miconazole nitrate capsule increased the serum concentrations of etonogestrel and ethinyl estradiol by approximately 17%
and 16% respectively. The clinical significance of these findings is unknown; however the contraceptive effectiveness of NuvaRing® is not expected to change.

Three consecutive daily doses of an oil-based 200 mg miconazole nitrate antimycotic suppository or a water-based 200 mg miconazole nitrate antimycotic vaginal cream resulted in mean serum concentrations of etonogestrel and ethinyl estradiol elevations of up to 40%. This effect was more pronounced with the oil-based suppository treatment than in the water-based cream treatment.

The effects of chronic administration of these products with NuvaRing® are unknown.

Intravaginal preparations
There have been reports of ring breakage during concomitant use of intravaginal preparations, including antimycotic, antibiotic and lubricant products (see WARNINGS AND PRECAUTIONS/Genitourinary/Disconnected/Broken Ring).

Drug-Food Interactions
Interactions with food have not been established.

Drug-Herb Interactions
Herbal products containing St. John’s wort(*) (* Hypericum perforatum) may induce hepatic enzymes (cytochrome P450) and p-glycoprotein transporter and may reduce the effectiveness of contraceptive steroids. This may also result in breakthrough bleeding. For short course, a barrier contraceptive method should be used in addition to NuvaRing® during administration and for 28 days after discontinuation of the herbal product. For long course, use another method of contraception.

Physicians and other health care providers should be made aware of the non-prescription products concomitantly used by the patient, including herbal and natural products.

Drug-Laboratory Test Interactions
Results of laboratory tests should be interpreted in the light that the patient is on combination hormonal contraceptives (including NuvaRing®). The following laboratory tests are modified.
A. Liver function tests
   Aspartate serum transaminase (AST) – variously reported elevations. Alkaline phosphatase and gamma glutamine transaminase (GGT) – slightly elevated.
B. Coagulation tests
   Minimal elevation of test values reported for such parameters as prothrombin and Factors VII, VIII, IX and X.
C. Thyroid function tests
   Protein binding of thyroxine is increased as indicated by increased total serum thyroxine concentrations and decreased T3 resin uptake.
D. Lipoproteins
   Small changes of unproven clinical significance may occur in lipoprotein cholesterol fractions.
E. Gonadotropins
   LH and FSH levels are suppressed by the use of oral contraceptives. Wait two weeks after discontinuing the use of oral contraceptives before measurements are made.
**Tissue Specimens**
Pathologists should be advised of combination hormonal contraceptive (including NuvaRing®) therapy when specimens obtained from surgical procedures and Pap smears are submitted for examination.

**Drug-Lifestyle Interactions**

**Vaginal Use**
NuvaRing® is designed to be a once-a-month contraceptive regimen, therefore, NuvaRing® should be left in the vagina for a continuous period of 3 weeks. Some women are aware of the ring at random times during the 21 days of use or during intercourse. During intercourse some sexual partners may feel NuvaRing® in the vagina. However, clinical studies revealed that 90% of couples did not find this to be a problem. NuvaRing® should not be removed during intercourse.

NuvaRing® may interfere with the correct placement and position of certain female barrier methods such as a diaphragm, cervical cap or female condom. These methods should not be used as back-up methods with NuvaRing®.

**Tampon Use**
The pharmacokinetics of NuvaRing® was evaluated in one cycle in 10 healthy female subjects randomized to tampon use (Kotex, regular strength) on Day 8, 9, 10 of the NuvaRing® cycle. The use of tampons had no effect on serum concentrations of etonogestrel and ethinyl estradiol during use of NuvaRing®. It is unknown how this affects the safety and efficacy of NuvaRing®.

**Expulsion**
NuvaRing® can be accidentally expelled, for example, when it has not been inserted properly, or while removing a tampon, during intercourse, or with straining during a bowel movement. Therefore, it is good habit for the woman to regularly verify the presence of NuvaRing® (for example, before and after intercourse). If NuvaRing® is accidentally expelled, the woman should follow the instructions given in DOSAGE AND ADMINISTRATION / Recommended Dose and Dosage Adjustment and Missed Dose.

Clinical trial data indicate that expulsion of NuvaRing® is most common in the first few cycles of use when women are becoming accustomed to this method of contraception. In a retrospective analysis of four one-year NuvaRing® trials it was found that expulsion occurred in 0.5% of cycles (N=33,462) and this percentage decreased to zero with duration of use (1.1% at cycle 1; N=3,228 and 0% at cycle 13; N=2,071)\(^{12}\). Overall, 2.3% of subjects (N=3,333) experienced expulsion over 13 cycles of use.

If the ring is accidentally expelled and is left outside of the vagina for less than 3 hours, contraceptive efficacy is not reduced. The vaginal ring can be rinsed with cool to lukewarm (not hot) water and re-inserted as soon as possible, but at the latest within 3 hours (see DOSAGE AND ADMINISTRATION – Missed Dose and INFORMATION FOR THE PATIENT – Missed Dose). If NuvaRing® is lost, a new vaginal ring should be inserted and the regimen should be continued without alteration.
If the ring has been out of the vagina for more than three hours during the 1st or 2nd week, contraceptive effectiveness may be reduced. The woman should reinsert the ring as soon as she remembers and an additional barrier method of contraception, such as a male condom and/or spermicide, MUST be used until the ring has been used **continuously for seven days**. The longer the time NuvaRing® has been out of the vagina and the closer this is to the ring-free interval, the higher the risk of a pregnancy.

If NuvaRing® has been out of the vagina for more than 3 hours during the 3rd week of the three-week use period contraceptive efficacy may be reduced. The woman should discard that ring, and one of the following two options should be chosen:

1. Insert a new ring immediately. Note: Inserting a new ring will start the next three-week use period. The woman may not experience a withdrawal bleed from her previous cycle. However, breakthrough spotting or bleeding may occur.
2. Have a withdrawal bleeding and insert a new ring no later than 7 days (7x24 hours) from the time the previous ring was removed or expelled. Note: This option should only be chosen if the ring was used continuously for the preceding 7 days.

Women with conditions affecting the vagina, such as a prolapsed uterus, may be more likely to have NuvaRing® slip out of the vagina.

**Non-Contraceptive Benefits of Combination Hormonal Contraceptives**
Several health advantages other than contraception have been reported.

1. Combination hormonal contraceptives reduce the incidence of cancer of the endometrium and ovaries.
2. Combination hormonal contraceptives reduce the likelihood of developing benign breast disease and as a result decrease the incidence of breast biopsies.
3. Combination hormonal contraceptives reduce the likelihood of development of functional ovarian cysts.
4. Combination hormonal contraceptive users have less menstrual blood loss and have more regular cycles, thereby reducing the chance of developing iron-deficiency anemia.
5. The use of combination hormonal contraceptives may decrease the severity of dysmenorrhea and premenstrual syndrome and may improve acne vulgaris, hirsutism and other androgen-mediated disorders.
6. Combination hormonal contraceptives decrease the incidence of acute pelvic inflammatory disease and thereby reduce as well the incidence of ectopic pregnancy.
7. Combination hormonal contraceptives have potential beneficial effects on endometriosis.

Confirmation is required as to whether these benefits also apply to NuvaRing®.
DOSSAGE AND ADMINISTRATION

Recommended Dose and Dosage Adjustment
To achieve maximum contraceptive effectiveness, NuvaRing® must be used as directed (see When to Start NuvaRing® below). One NuvaRing® is inserted in the vagina by the woman herself. As NuvaRing® is designed to be a once-a-month contraceptive regimen the ring is to remain in place continuously for three weeks. It is removed for a one-week break, during which a withdrawal bleed usually occurs. A new ring is inserted no more than one week after removal of the last ring.

Advise women to regularly check for the presence of NuvaRing® in the vagina (for example, before and after intercourse). If NuvaRing® is accidentally expelled, the woman should follow the instructions given below (Missed Dose / ‘Inadvertent removal, expulsion, or prolonged ring-free interval’ (for more information, see also DRUG INTERACTIONS / Drug-Lifestyle Interactions / Expulsion).

Missed Dose
Inadvertent removal, expulsion, or prolonged ring-free interval
NuvaRing® should be left in the vagina for a continuous period of 3 weeks. If the ring is accidentally expelled and is left outside of the vagina for less than 3 hours contraceptive efficacy is not reduced i.e., the woman should still be protected from pregnancy. NuvaRing® should be rinsed with cool to lukewarm (not hot) water and re-inserted as soon as possible, but at the latest within 3 hours. If NuvaRing® is lost, a new vaginal ring should be inserted and the regimen should be continued without alteration.

If NuvaRing® is out of the vagina for more than 3 continuous hours:
During Weeks 1 and 2: If NuvaRing® has been out of the vagina for more than 3 continuous hours during the 1st or 2nd week of use, contraceptive efficacy may be reduced. The woman should reinsert the ring as soon as she remembers. A barrier method, such as a male condom and/or spermicide, must be used in addition until NuvaRing® has been in the vagina continuously for 7 days. The longer the time NuvaRing® has been out of the vagina and the closer this is to the ring-free interval, the higher the risk of pregnancy.

During Week 3: If NuvaRing® has been out of the vagina for more than 3 continuous hours during the 3rd week of the three-week use period, contraceptive efficacy may be reduced. The woman should discard that ring, and one of the following two options should be chosen:

1. Insert a new ring immediately. Inserting a new ring will start the next three-week use period. The woman may not experience a withdrawal bleed from her previous cycle. However, breakthrough spotting or bleeding may occur.

2. Have a withdrawal bleeding and insert a new ring no later than 7 days (7x24 hours) from the time the previous ring was removed or expelled. This option should only be chosen if the ring was used continuously for the preceding 7 days.

A barrier method such as male condoms and/or spermicides must be used until the new ring has been used continuously for seven days.
If the ring-free interval has been extended beyond one week, the possibility of pregnancy should be considered, and an additional method of contraception, such as a male condom and/or spermicide, **MUST** be used until NuvaRing® has been used **continuously for seven days**. The longer the ring-free interval, the higher the risk of pregnancy.

If NuvaRing® was out of the vagina for an unknown amount of time, the possibility of pregnancy should be considered. A pregnancy test should be performed prior to inserting a new ring.

**Administration**
The user can choose the insertion position that is most comfortable to her, for example, standing with one leg up, squatting, or lying down. The ring is to be compressed and inserted into the vagina until it feels comfortable. The exact position of NuvaRing® inside the vagina is not critical for the contraceptive effect of the ring. The vaginal ring must be inserted on the appropriate day and left in place for three consecutive weeks. This means that the ring is removed three weeks later on the same day of the week as it was inserted and at about the same time. NuvaRing® can be removed by hooking the index finger under the forward rim or by grasping the rim between the index and middle finger and pulling it out. The used ring should be placed in the sachet (foil pouch) and discarded in a waste receptacle out of the reach of children and pets (do not flush in toilet). The withdrawal bleeding usually starts 2-3 days after removal of the ring and may not have finished before the next ring is inserted. In order to maintain contraceptive effectiveness, the new ring must be inserted one week after the previous one was removed even if menstrual bleeding has not finished. For example, if NuvaRing® is inserted on Wednesday at 22:00 h the ring should be removed again on the Wednesday 3 weeks later at about 22:00 h. The following Wednesday a new ring should be inserted.

**When to Start NuvaRing®**
IMPORTANT: The possibility of ovulation and conception prior to the first use of NuvaRing® should be considered.

**No hormonal contraceptive use in the preceding cycle**
The woman may start using NuvaRing® within the first five days of her natural cycle (i.e., Day 1-5 of her menstrual bleeding). During the first seven days of NuvaRing® use in the first cycle, an additional barrier method, such as male condoms or spermicide, is recommended.

**Switching from another combination hormonal contraceptive**
The woman may switch from her previous combined hormonal contraceptive on any day of the cycle, if she has been using this method consistently and correctly, and if it is reasonably certain that she is not pregnant. Otherwise, the woman should insert NuvaRing® at the latest on the day following the usual tablet-free, patch-free or placebo tablet interval of her previous combined hormonal contraceptive. The hormone-free interval of the previous method should never be extended beyond its recommended length.

**Switching from a progestin-only method**
There are several types of progestin-only methods. Women should insert the first NuvaRing® as follows:
- Any day of the month when switching from a progestin-only pill; do not skip any days between the last pill and the first day of NuvaRing® use
- On the same day as contraceptive implant removal
- On the same day as removal of a progestin-containing IUD, or
- On the day when the next contraceptive injection would be due

In all of these cases, the patient should be advised to use an additional method of contraception, such as a male condom and/or spermicide, for the first seven days after insertion of the ring.

**Following complete first-trimester abortion**
The woman may start using NuvaRing® within the first five days following a complete first trimester abortion and does not need to use an additional method of contraception. If use of NuvaRing® is not started within five days following a first trimester abortion, the woman should follow the instructions for “No preceding hormonal contraceptive use in the preceding cycle.” In the meantime she should be advised to use a non-hormonal contraceptive method.

**Following delivery or second-trimester abortion**
The use of NuvaRing® for contraception may be initiated four weeks after a second trimester abortion or four weeks postpartum in women who elect not to breastfeed. When NuvaRing® is used postpartum or postabortion, the increased risk of thromboembolic disease must be considered. (See CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS / Hematologic concerning thromboembolic disease. Also see WARNINGS AND PRECAUTIONS / Special Populations / Nursing Women regarding breastfeeding.) If a woman begins using NuvaRing® postpartum, she should be instructed to use an additional method of contraception, such as male condoms or spermicide for the first seven days. If she has not yet had a period, the possibility of ovulation and conception occurring prior to initiation of NuvaRing® should be considered.

The increased risk of VTE during postpartum period should be considered when restarting NuvaRing® (see WARNING AND PRECAUTIONS / Hematologic)

**Deviations from the Recommended Regimen**
To prevent loss of contraceptive efficacy patients should not deviate from the recommended regimen.

**Prolonged Use of NuvaRing®**
If NuvaRing® has been left in place for up to one extra week (i.e., up to four weeks total), the woman will remain protected. NuvaRing® should be removed and the woman should insert a new ring after a one-week ring-free interval. The mean serum etonogestrel concentration during the fourth week of continuous use of NuvaRing® was 1,272 ± 311 pg/mL compared to a mean concentration range of 1,578 ± 408 to 1,374 ± 328 pg/mL during Weeks 1 to 3. The mean serum ethinyl estradiol concentration during the fourth week of continuous use of NuvaRing® was 16.8 ± 4.6 pg/mL compared to a mean concentration range of 19.1 ± 4.5 to 17.6 ± 4.3 pg/mL during Weeks 1 to 3. If NuvaRing® has been left in place for longer than four weeks, contraceptive efficacy may be reduced. Pregnancy should be ruled out before inserting a new NuvaRing®, and an additional method of contraception, such as a male condom and/or spermicide, MUST be used until the new NuvaRing® has been used continuously for seven days.
**In the Event of a Missed Menstrual Period**

1. If the patient has not adhered to the prescribed regimen (NuvaRing® has been out of the vagina for more than three hours or the preceding ring-free interval was extended beyond one week) the possibility of pregnancy should be considered at the time of the first missed period and NuvaRing® use should be discontinued if pregnancy is confirmed.

2. If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out.

3. If the patient has retained one NuvaRing® for longer than four weeks, pregnancy should be ruled out.

**How to Change the NuvaRing® Start Day to another Day of the Week**

If the woman wishes to change the day on which she starts a new NuvaRing® cycle, she should complete the current cycle, removing NuvaRing® on the same day of the week as the one on which she started. During the ring-free period, a new start day may be selected by inserting the new NuvaRing® on the first occurrence of the desired day. In no case should there be more than 7 consecutive ring-free days. The shorter the ring-free interval, the higher the risk that she does not have a withdrawal bleed and may experience breakthrough bleeding and spotting during the use of the next ring. This practice is for a one-time only change and should not to be used as a standard dosing regimen, as there are no long-term safety data available on the continuous use of NuvaRing®.

**OVERDOSAGE**

Overdosage of combination hormonal contraceptives may cause nausea, vomiting, vaginal bleeding, or other menstrual irregularities. Given the nature and design of NuvaRing®, it is unlikely that overdosage will occur. If a NuvaRing® is broken, it does not release a higher dose of hormones. Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. There are no antidotes and further treatment should be symptomatic.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

**ACTION AND CLINICAL PHARMACOLOGY**

NuvaRing® is a non-biodegradable, flexible, transparent, colorless to almost colorless, combination contraceptive vaginal ring containing two active components, a progestin, etonogestrel and an estrogen, ethinyl estradiol. When placed in the vagina, each ring releases on average 120 µg/day of etonogestrel and 15 µg/day of ethinyl estradiol over a three-week period of use. NuvaRing® is made of ethylene vinylacetate copolymers and magnesium stearate and contains 11.4 mg etonogestrel and 2.6 mg ethinyl estradiol. NuvaRing® has an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. It does not contain any latex.
Mechanism of Action
Combination hormonal contraceptives (including NuvaRing®) act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduces the likelihood of implantation).

Pharmacodynamics
Etonogestrel, the progestogen component of NuvaRing®, displays low androgenic activity in relation to its progestogenic effects and may increase the HDL₁-, HDL₂-, and HDL₃-cholesterol and apoprotein A-1/B ratio without affecting LDL. Like other hormonal contraceptives, these changes in lipid profile can be associated with an increase in triglycerides.

Pharmacokinetics
The pharmacokinetic parameters of etonogestrel and ethinyl estradiol were determined during one cycle of NuvaRing® use in 16 healthy female subjects and are summarized in Table 6.

Table 6 – Summary of NuvaRing®’s Pharmacokinetic Parameters in 16 healthy female subjects

<table>
<thead>
<tr>
<th></th>
<th>C&lt;sub&gt;max&lt;/sub&gt; mean (SD) pg/mL</th>
<th>t&lt;sub&gt;1/2&lt;/sub&gt; (h)</th>
<th>T&lt;sub&gt;max&lt;/sub&gt; (h)</th>
<th>Clearance (L/h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etonogestrel</td>
<td>1,716 (445) 34.7 (17.5)</td>
<td>29.3 (6.1) 44.7 (28.8)</td>
<td>200.3 (69.9) 59.3 (67.5)</td>
<td>3.4 (0.8) 34.8 (11.6)</td>
</tr>
<tr>
<td>Ethinyl Estradiol</td>
<td>19.1 (4.5) 18.3 (4.3)</td>
<td>17.6 (4.3)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C<sub>max</sub> - maximum serum drug concentration
T<sub>max</sub> - time at which maximum serum drug concentration occurs
t<sub>1/2</sub> - elimination half-life, calculated by 0.693/K<sub>elim</sub>
CL - apparent clearance

Absorption:
Etonogestrel: Etonogestrel released by NuvaRing® is rapidly absorbed. The bioavailability of etonogestrel after vaginal administration is approximately 100%. The serum etonogestrel and ethinyl estradiol concentrations (pg/mL) observed during three weeks of NuvaRing® use are summarized in Table 6.

Ethinyl estradiol: Ethinyl estradiol released by NuvaRing® is rapidly absorbed. The bioavailability of ethinyl estradiol after vaginal administration is approximately 55.6%, which is comparable to that with oral administration of ethinyl estradiol. However, the overall systemic exposure to ethinyl estradiol with NuvaRing® was approximately 50% of that for a 30 mcg oral contraceptive reflecting the difference in daily doses (15 µg vs. 30 µg). The serum ethinyl estradiol concentrations observed during three weeks of NuvaRing® use are summarized in Table 7.

Table 7 – Mean (SD) Serum Etonogestrel and Ethinyl Estradiol Concentrations (n=16)

<table>
<thead>
<tr>
<th></th>
<th>1 week</th>
<th>2 weeks</th>
<th>3 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etonogestrel (pg/mL)</td>
<td>1,578 (408)</td>
<td>1,476 (362)</td>
<td>1,374 (328)</td>
</tr>
<tr>
<td>Ethinyl estradiol (pg/mL)</td>
<td>19.1 (4.5)</td>
<td>18.3 (4.3)</td>
<td>17.6 (4.3)</td>
</tr>
</tbody>
</table>

The pharmacokinetic profile of etonogestrel and ethinyl estradiol during use of NuvaRing® is shown in Figure 1.
Serum ethinyl estradiol levels were measured in a comparative randomized trial (n=24) with NuvaRing® (daily vaginal EE release of 0.015 mg), a transdermal patch (norelgestromin/EE; daily EE release of 0.020 mg) and a COC (levonorgestrel/EE; daily EE release of 0.030 mg) during one cycle in healthy female subjects. The monthly systemic ethinyl estradiol exposure ($AUC_{0-\infty}$) of NuvaRing® was 10.9 ng·h/mL.

**Distribution:** Etonogestrel was found to be 98% protein bound, primarily to albumin and sex hormone-binding globulin (SHBG). The apparent volume of distribution of etonogestrel is 2.3 L/kg.

Ethinyl estradiol: Ethinyl estradiol is highly but not specifically bound to serum albumin (98.5%) and induces an increase in the serum concentrations of SHBG. An apparent volume of distribution of about 15 L/kg has been determined.

**Metabolism:** In vitro data shows that both etonogestrel and ethinyl estradiol are metabolized in liver microsomes by the cytochrome P450 3A4 isoenzyme. Ethinyl estradiol is primarily metabolized by aromatic hydroxylation, but a wide variety of hydroxylated and methylated metabolites are formed. These are present as free metabolites and as sulfate and glucuronide conjugates. The hydroxylated ethinyl estradiol metabolites have weak estrogenic activity. The biological activity of etonogestrel metabolites is unknown.

**Excretion:** Etonogestrel and ethinyl estradiol are primarily eliminated in urine, bile and feces.

**Special Populations and Conditions**

**Pediatric Populations:** The pharmacokinetics of NuvaRing® in healthy postmenarchal female adolescents under the age of 18 has not been studied.

**Race:** No formal studies were conducted to evaluate the effect of race on the pharmacokinetics of NuvaRing®.
Hepatic Insufficiency: No formal studies were conducted to evaluate the effect of hepatic
disease on the pharmacokinetics, safety, and efficacy of NuvaRing®. However, steroid hormones
may be poorly metabolized in patients with impaired liver function. Acute or chronic
disturbances of liver function may necessitate the discontinuation of CHC use until markers of
liver function return to normal (see CONTRAINDICATIONS and WARNINGS AND
PRECAUTIONS).

Renal Insufficiency: No formal studies were conducted to evaluate the effect of renal disease on
the pharmacokinetics, safety, and efficacy of NuvaRing®.

STORAGE AND STABILITY

Prior to dispensing to the user, store refrigerated at 2-8°C. After dispensing to the user,
NuvaRing® (etonogestrel/ethinyl estradiol slow release vaginal ring) can be stored for up to 4
months at 2-30°C. Avoid storing NuvaRing® at temperatures above 30°C. Protect from light.

For the Dispenser
When NuvaRing® is dispensed to the user, place an expiration date on the label. The date should
not exceed either 4 months from the date of dispensing or the expiration date, whichever comes
first. Store between 2-30°C.

Keep in a safe place out of the reach of children and pets.

SPECIAL HANDLING INSTRUCTIONS

After removal, NuvaRing® should be replaced in the reclosable sachet and disposed of with the
normal household waste in a manner that avoids accidental contact with others. NuvaRing®
should not be flushed down the toilet.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Each NuvaRing® is individually packaged in a reclosable aluminum laminate sachet consisting of
three layers, from outside to inside: Polyethylene terephthalate (PET), aluminum foil, and low-density
polyethylene.

NuvaRing® has an outer diameter of 54 mm and a cross-sectional diameter of 4 mm.

Each ring contains 11.4 mg etonogestrel and 2.6 mg ethinyl estradiol Ph.Eur. and delivers
120 mcg etonogestrel and 15 mcg ethinyl estradiol per day. NuvaRing® also contains ethylene
vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate. NuvaRing® does
not contain any latex.

NuvaRing® is available in: Boxes of 3 sachets
Boxes of 1 sachet
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

I. Progestogen

Proper Name: Etonogestrel

Chemical Name:
1) 18,19-Dinor-17α-pregn-4-en-20-yn-3-one,13-ethyl-17-hydroxy-11-methylene-;
2) 13-Ethyl-17-hydroxy-11-methylene-18,19-dinor-17α-pregn-4-en-20yn-3-one.
3) (17α)13-ethyl-17-hydroxy-11-methylene-18,19- dinorpregn-4-en-20-yn-3-one.

Molecular Formula: C_{22}H_{28}O_{2}

Molecular Weight: 324.46

Structural Formula:

![Structural formula of Etonogestrel]

Physical Form: White to practically white crystalline powder which may have a slight odour.

Solubility:
- At 22°C: n-Hexane - 2 mg/mL
- Ethanol (96%) - 60 mg/mL
- Ethyl acetate - 60 mg/mL
- Water - practically insoluble

Melting Point: 197.6°C
II. Estrogen

Proper Name: Ethinyl Estradiol Ph.Eur.
Chemical Name: 19-Nor-17α-pregna-1,3,5(10)-trien-20-yn-3,17-diol
Molecular Formula: C₂₀H₂₄O₂
Molecular Weight: 296.4
Structural Formula:

Physical Form: White, crystalline powder
Solubility: Soluble in ethanol, ether, acetone, chloroform.
Practically insoluble in water.
Melting Point: 182-184°C
CLINICAL TRIALS

Study demographics and trial design

Table 8 – Summary of patient demographics for clinical trials in specific indication

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design</th>
<th>Dosage, route of administration and duration</th>
<th>Study subjects (n=number)</th>
<th>Mean age (Range)</th>
<th>Gender</th>
<th>Primary endpoint</th>
<th>Secondary endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>068003</td>
<td>Open-label, non-comparative, multicenter, efficacy, cycle control, safety</td>
<td>Declared daily release rate of 0.120 mg ENG and 0.015 mg EE, vaginal – 13 cycles</td>
<td>1,177 1,145</td>
<td>28.1 28.2 (18-41) (18-41)</td>
<td>F 2</td>
<td>Contraception – Primary efficacy was based on contraceptive efficacy, ie, on the prevention of in-treatment pregnancies. Pearl indices (representing the expected number of pregnancies per 100 women-years of exposure) and overall cumulative probability of in-treatment pregnancy are estimated to evaluate the contraceptive efficacy of NuvaRing®.</td>
<td>Cycle control – The statistical analysis of the cycles focused on the following parameters: occurrence of breakthrough bleeding/spotting • absence of withdrawal bleeding/spotting • occurrence of breakthrough bleeding • occurrence of breakthrough spotting (spotting only) • occurrence of early withdrawal bleeding • occurrence of continued withdrawal bleeding • number of breakthrough bleeding/spotting days • number of withdrawal bleeding (days) • occurrence of early withdrawal bleeding with only spotting days in the ring period • occurrence of continued withdrawal bleeding continued with spotting days only • occurrence of intended bleeding pattern</td>
</tr>
</tbody>
</table>

Study Results – Pivotal Trials

a) Contraceptive Efficacy – Pearl Index

Clinical studies were performed worldwide in women between the age of 18 and 40 years.

In 2 large pivotal clinical trials of 13 cycles of NuvaRing® (etongestrel/ethinyl estradiol slow release vaginal ring) use, pregnancy rates were between 1 and 2 per 100 women-years of use.

b) Cycle Control

Relative frequencies of bleeding/spotting and bleeding days showed a consistent pattern throughout all 13 cycles for the pivotal studies combined. The majority of subjects were bleeding/spotting during the ring-free period. The relative frequencies of bleeding days were acceptable during almost all ring period days.
For the combined pivotal studies, incidences of bleeding variables over Cycles 1-13 were acceptable and comparable to that of other combined hormonal contraceptives (Table 9). The incidence of breakthrough bleeding/spotting ranged from 5.1% - 7.9% and the incidence of absence of withdrawal bleeding ranged from 1.5% - 2.9% of Intent-to-Treat (ITT) evaluable cycles. Per Protocol (PP) cycles exhibited lower incidences than ITT cycles (Figure 2). Early (ranges 5.6% - 8.8%) and continued withdrawal bleeding (ranges 19.5% to 25.2%) consisted mostly of spotting days only. The incidence of intended bleeding pattern, which is representative of an “ideal” bleeding pattern where bleeding occurs primarily during the ring-free period (without breakthrough bleeding/spotting, without absence of withdrawal bleeding, without absence of early and continued (in the next cycle) withdrawal bleeding), over Cycles 1-12 ranged from 59.9% - 68.5% of ITT evaluable cycles. The incidences of intended bleeding pattern were comparable between ITT and PP cycles.

Table 9 – Parameters of Bleeding Pattern during the First Year of use – Combined Pivotal Studies

<table>
<thead>
<tr>
<th>Cycle</th>
<th>Number of Evaluable Cycles</th>
<th>Number of Evaluable Cycles</th>
<th>Incidence of Breakthrough Bleeding/Spotting (%)</th>
<th>Incidence of Absence of Withdrawal Bleeding (%)</th>
<th>Incidence of Intended Bleeding Pattern (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ITT</td>
<td>PP</td>
<td>ITT</td>
<td>PP</td>
<td>ITT</td>
<td>PP</td>
</tr>
<tr>
<td>1</td>
<td>1,971</td>
<td>1,709</td>
<td>7</td>
<td>5.9</td>
<td>2.9</td>
</tr>
<tr>
<td>2</td>
<td>1,796</td>
<td>1,368</td>
<td>7.9</td>
<td>6.6</td>
<td>2.1</td>
</tr>
<tr>
<td>6</td>
<td>1,649</td>
<td>1,299</td>
<td>6.2</td>
<td>5.7</td>
<td>1.5</td>
</tr>
<tr>
<td>9</td>
<td>1,499</td>
<td>1,177</td>
<td>6.0</td>
<td>4.8</td>
<td>2.4</td>
</tr>
<tr>
<td>12</td>
<td>1,300</td>
<td>1,053</td>
<td>6.6</td>
<td>5.3</td>
<td>2.2</td>
</tr>
<tr>
<td>13</td>
<td>948</td>
<td>734</td>
<td>5.5</td>
<td>3.5</td>
<td>2.2</td>
</tr>
</tbody>
</table>

ITT = Intent-to-Treat; PP = Per Protocol

Figure 2 – Incidence of Breakthrough Bleeding/Spotting (BTB/S) – Combined Pivotal Studies

ITT = Intent-to-Treat; PP = Per Protocol
c) Tolerance
Acceptability of NuvaRing® was evaluated in the pivotal studies on the basis of answers to questions completed by each subject at different timepoints during the studies. Acceptability data from last assessment related to the use of NuvaRing® are presented in Table 10. Nearly all women found the ring easy to insert and remove. Eighteen percent of women reported at least occasionally feeling the ring during intercourse. Although this response was higher for the question of partners feeling the ring, 94% of completers’ partner and 83% of discontinuers’ partner did not object to women using the ring.

Table 10 – Responses from Acceptability Questionnaire at Last Assessment – Combined Pivotal Studies

<table>
<thead>
<tr>
<th>Population</th>
<th>Number of responders</th>
<th>Proportion of subjects responding</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Never/rarely</td>
</tr>
<tr>
<td>Was the ring easy to insert?</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Completers</td>
<td>1,499</td>
<td>4</td>
</tr>
<tr>
<td>Discontinuers</td>
<td>643</td>
<td>2</td>
</tr>
<tr>
<td>Combined</td>
<td>2,142</td>
<td></td>
</tr>
<tr>
<td>Was the ring easy to remove?</td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Completers</td>
<td>1,499</td>
<td>2</td>
</tr>
<tr>
<td>Discontinuers</td>
<td>642</td>
<td>1</td>
</tr>
<tr>
<td>Combined</td>
<td>2,141</td>
<td></td>
</tr>
<tr>
<td>Could feel ring during intercourse?</td>
<td></td>
<td>85</td>
</tr>
<tr>
<td>Completers</td>
<td>1,498</td>
<td>77</td>
</tr>
<tr>
<td>Discontinuers</td>
<td>630</td>
<td>83</td>
</tr>
<tr>
<td>Combined</td>
<td>2,128</td>
<td></td>
</tr>
<tr>
<td>Could partner feel ring during intercourse?</td>
<td></td>
<td>71</td>
</tr>
<tr>
<td>Completers</td>
<td>1,498</td>
<td>63</td>
</tr>
<tr>
<td>Discontinuers</td>
<td>631</td>
<td>68</td>
</tr>
<tr>
<td>Combined</td>
<td>2,129</td>
<td></td>
</tr>
<tr>
<td>Did partner mind you using the ring?</td>
<td></td>
<td>94</td>
</tr>
<tr>
<td>Completers</td>
<td>1,498</td>
<td>83</td>
</tr>
<tr>
<td>Discontinuers</td>
<td>635</td>
<td>91</td>
</tr>
<tr>
<td>Combined</td>
<td>2,133</td>
<td></td>
</tr>
</tbody>
</table>

Ninety-six percent (96%) of completers at cycle 13 reported that they were satisfied with the ring and 97% would recommend this method to others. Eighty-five percent (85%) of all women (completers and premature study discontinuers) were satisfied with the use of NuvaRing® and 90% would recommend this method to others.

d) Safety
In the combined pivotal non-controlled open-label studies 351/2322 (15.1%) treated subjects discontinued due to AEs; most were drug-related AEs. The most common AEs leading to discontinuation of women were device related events (2.5%): foreign-body sensation, coital problems, device expulsion, vaginal symptoms (discomfort/vaginitis/leukorrhea), headache (1.3%), emotional lability (1.2%), and weight increase (1.0%).

Over the 13 cycles of treatment, the mean increase in body weight from baseline was 0.84 kg. Similarly, there was no clinically relevant change from baseline in blood pressure (Table 11).
Table 11 – Mean Change (± standard deviation) in Blood Pressure and Body Weight from Baseline – Combined Pivotal Studies (ITT)

<table>
<thead>
<tr>
<th></th>
<th>3</th>
<th>6</th>
<th>9</th>
<th>13</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diastolic (mmHg)</strong></td>
<td>-0.1±8.4</td>
<td>-0.3±8.9</td>
<td>0.0±8.7</td>
<td>0.5±8.9</td>
</tr>
<tr>
<td><strong>Systolic (mmHg)</strong></td>
<td>-0.2±10.3</td>
<td>-0.1±11.0</td>
<td>-0.2±11.0</td>
<td>0.6±11.2</td>
</tr>
<tr>
<td><strong>Body weight (kg)</strong></td>
<td>0.02±2.29</td>
<td>0.05±3.12</td>
<td>0.47±3.40</td>
<td>0.84±3.81</td>
</tr>
</tbody>
</table>

Subjects withdrew at a rate of <1.0% for the following reasons: bleeding irregularities, vaginal discomfort, vaginitis, nausea, and leukorrhea.

**Comparative Trials – Cycle Control**
In 3 metabolic studies, the secondary objective was to examine cycle control and tolerability in NuvaRing® users compared to a 150 μg levonorgestrel/30 μg ethinyl estradiol combined oral contraceptive group (COC). All three trials were of similar design to permit pooling of the data for all 6 cycles.

Relative frequencies of bleeding/spotting and bleeding days showed a consistent pattern throughout all 6 cycles for both treatment groups, except for Cycle 1 in the COC group. In the NuvaRing® group, the relative frequencies of bleeding/spotting during the ring-free periods reached a maximum of at least 92.6% per cycle in the ITT analysis. In the COC group, the relative frequencies of bleeding/spotting during the ring-free periods reached a maximum of at least 91.8% per cycle. The relative frequencies of bleeding/spotting days are low during the ring/pill period beginning from the second half of the first week onwards while the relative frequencies of bleeding days are extremely low during almost all ring/pill period days.

Withdrawal bleeding occurred in nearly all cycles for both groups, 98.2 - 100%. Incidences of early withdrawal bleeding (Cycles 1-6) were low in both groups (1.3% to 13.0% in the NuvaRing® group, and 1.8% to 10.3% in the COC group). Continued withdrawal bleedings (over Cycles 1-5) ranged from 17.4% to 28.0% in the NuvaRing® group and from 45.9% to 57.1% in the LNG/EE OC group. This difference was statistically significant. In both groups early withdrawal bleeding and continued bleeding consisted mostly of spotting days only.

Incidences of breakthrough bleeding/spotting episodes for the NuvaRing® group over Cycles 1-6 ranged from 1.1% - 5.0% (Table 12). In the COC group, these incidences over Cycles 2-6 ranged from 5.4% - 11.0%, whereas in Cycle 1 the incidence was 38.8%. This observed difference for Cycle 1 was statistically significant. Note that, for Cycle 1, the NuvaRing® group inserted the ring on Day 5 of the menstrual period, whereas the LNG/EE group started pill intake on Day 1. To allow for this difference, a correction was made during data analysis by excluding the first seven days of Cycle 1.
The incidence of intended bleeding pattern for the NuvaRing® group was significantly higher over Cycles 1-5 (ranging from 65.3% - 68.4%) than the COC group (ranging from 28.4% - 46.8%) (Table 12). The high incidences of intended bleeding pattern during Cycle 6 (93.8% in the NuvaRing® group and 91.4% in the COC group) were due to continued withdrawal bleedings not being reported, since it would have required post-treatment bleeding data.

Table 12 – Cycle control in combined metabolic studies (NuvaRing® n=121; COC n=126) (ITT)

<table>
<thead>
<tr>
<th>Cycle</th>
<th>Incidence of Breakthrough Bleeding/Spotting (%)</th>
<th>NuvaRing®</th>
<th>COC</th>
<th>Incidence of Intended Bleeding Pattern (%)</th>
<th>NuvaRing®</th>
<th>COC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.9</td>
<td>38.8</td>
<td>65.4</td>
<td>28.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>10.7</td>
<td>68.3</td>
<td>35.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>3.1</td>
<td>10.1</td>
<td>65.3</td>
<td>44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>1.1</td>
<td>6.3</td>
<td>68.4</td>
<td>46.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>4.3</td>
<td>11</td>
<td>66.3</td>
<td>45.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>5</td>
<td>5.4</td>
<td>93.8</td>
<td>91.4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A subsequent large comparative study with 150/30μg LNG/EE OC (n=512 vs n=518) evaluating vaginal bleeding characteristics over 13 cycles showed the incidence of breakthrough bleeding/spotting for NuvaRing® ranged from 2.0 - 6.4%. The incidence of intended bleeding pattern for NuvaRing® ranged from 58.8 - 72.8%.

Overall, the cycle control achieved during NuvaRing® use was excellent and better than that in women who used an oral contraceptive for many of the parameters that were examined.

**Metabolic Studies**

Lipid Metabolism Study

A causal relationship between ischemic heart disease and unfavorable plasma lipid/lipoprotein profiles, specifically, a high LDL/HDL ratio, is now widely accepted on the basis of epidemiologic, biochemical and other evidence. It has also been demonstrated that androgens influence the lipid/lipoprotein ratio unfavourably, while estrogens have a beneficial effect, largely by increasing HDL₂ and, to a lesser extent, by reducing LDL levels.

NuvaRing® had generally favorable effects on lipids. In a clinical study involving 40 NuvaRing®-treated subjects, the following effects on lipid metabolism parameters were observed: total cholesterol (Total-C) was unchanged, high-density lipoprotein cholesterol (HDL-C) was unchanged, LDL₂ increased 26.3%, HDL₃ decreased 4.6%, low-density lipoprotein cholesterol (LDL-C) was unchanged, triglycerides increased 23.8%, apolipoprotein A-1 (apo A-1) increased 10.3%, apolipoprotein B (apo B) increased 6.2%, and lipoprotein (a) decreased 12.9%.
In the same clinical study NuvaRing® was also compared to a levonorgestrel/ethinyl estradiol oral contraceptive group (LNG/EE OC). Total cholesterol levels remained more or less unchanged in both groups. However, HDL-, HDL2-, and HDL3- cholesterol levels were significantly higher in NuvaRing® group than in the LNG/EE OC group. Levels of HDL-, HDL2-, and HDL3- cholesterol were decreased from baseline in the LNG/EE OC group and unchanged (HDL), increased (HDL2) and slightly decreased (HDL3) in NuvaRing® group. LDL-cholesterol levels were significantly lower in NuvaRing® group, due to an increase in the LNG/EE OC group and no change or decrease in NuvaRing® group. Triglyceride levels were increased in both groups. No significant difference between the two groups was noted. Group comparisons indicated significantly higher apolipoprotein A-I levels for the NuvaRing® group. No treatment differences for apolipoprotein B levels were observed. Compared to baseline, levels increased in the two groups, except for apolipoprotein A-I that decreased in the LNG/EE OC group. Lipoprotein (a) levels were decreased in both groups. No significant difference between the two groups was noted.

The magnitude of the effect of a combined hormonal contraceptive on plasma SHBG depends on both the estrogen dose and the dose and hormonal profile of the progestogenic component. A progestogen with low androgenic activity, such as etonogestrel, is expected to induce higher SHBG concentrations as compared to the ones with higher androgenic activity. Comparison between two treatment groups showed a significantly higher increase of adjusted SHBG levels for the NuvaRing® group (62% at Cycle 6) than the LNG/EE OC group. At Cycle 6, relative increases from baseline were 170% for the NuvaRing® group and 56% for the LNG/EE OC group.

Hemostasis Study
A specific hemostasis study (n=44) was performed with NuvaRing®. In addition to conventional parameters such as fibrinogen, plasminogen, tissue plasminogen activator and plasminogen activator inhibitor-I antigen, a number of new assays have been introduced. These assays detect markers that are generated in the proteolytic process of the thrombin-generating or fibrinolytic cascade and, in contrast to the more conventional parameters mentioned before, are considered to reflect the ‘in vivo’ hemostasis activity. Therefore they may be more predictive of a pre-thrombotic state (Winkler et al., 1995) than the conventional parameters. This concerns the procoagulation parameters prothrombin fragment 1 and 2 and the thrombin-antithrombin III complex, which are indicative of thrombin generation, and the profibrinolysis parameter plasmin-antiplasmin complex and fibrin turnover parameters such as D-dimer and fibrinogen degradation products as markers of the fibrinolytic cascade. Of further importance are Factor VII because it reflects ongoing coagulatory activity and the anticoagulation parameters antithrombin III, protein C and protein S, because women with a deficiency in any of these factors may not be able to adjust sufficiently to changes induced by external factors.

The effects of NuvaRing® on the above mentioned hemostasis parameters were investigated in an open-label, group-comparative study with a 0.150 mg LNG and 0.030 mg EE containing OC. The effects on the coagulation and fibrinolysis parameters seen in the NuvaRing® group were not statistically different from the effects seen in the LNG/EE OC group, except for the relatively higher increase of the procoagulation parameter Factor VII and the anticoagulation parameter Protein C, and the relative less decrease of the profibrinolysis parameter t-PA in the NuvaRing® group. No difference between the two treatment groups was observed for fibrin turnover. Both in
NuvaRing® and in the LNG/EE OC group most of the hemostatic parameters that were investigated showed (small) changes from baseline. The clinical relevance of all these changes is not clear. The hemostatic system is very complex and intricately balanced; to a certain extent, the intrinsic balancing system can overcome the activation/inhibition of one or more of the hemostatic parameters. Furthermore, it is very difficult to correct for a possible natural rhythm, which hampers interpretation of changes from baseline. Nevertheless, both NuvaRing® and the LNG/EE OC had no effect on the end products of the fibrinolytic cascade, namely the fibrin degradation products.

In view of the knowledge that individual women might have increased susceptibility for thrombosis, the data obtained with NuvaRing® and the LNG/EE OC were also compared on an individual basis, with emphasis on women having one or more hemostasis parameters outside the reference ranges. During the study most of the subjects in both treatment groups had one or more in-treatment values outside the reference range. However, none were clinically significant nor considered clinically relevant by the investigator.

In conclusion, although for some parameters differences were observed between NuvaRing® and the LNG/EE OC, there was no evidence of a pronounced disturbance of the hemostatic balance with either product. Furthermore, both NuvaRing® and the LNG/EE OC had no effect on the end products of the fibrinolytic cascade, namely the fibrin degradation products.

Carbohydrate Metabolism Study
In another metabolic study (n=37) there was less of an effect on the adrenal function parameter total cortisol with NuvaRing® than with LNG/EE OC. The thyroid function parameter TSH showed a significantly higher relative increase in the NuvaRing® group at Cycle 3, but not at the Cycle 6 assessment. Free thyroxin levels were unchanged compared to baseline in both groups. The effects on carbohydrate metabolism parameters seen in the NuvaRing® group were similar to the effects seen in the LNG/EE OC group.

Bone Mineral Density
A controlled open-label, multicenter trial was conducted to evaluate the effects of NuvaRing® on bone mineral density (BMD) in healthy young women (n=105; 76 completers) over a 2 year period (26 cycles). The control group (n=39; 31 completers) consisted of women who did not use a hormonal method of contraception, and an IUD was offered as trial medication. The mean age of subjects was 27 years in the NuvaRing® group and 29 years in the control group.

For the NuvaRing® group, the BMD for lumbar spine and femoral neck were not statistically different from baseline after two years of follow-up (change in z-score was –0.093 and –0.048, respectively). In the control group, a slight increase of BMD for both the lumbar spine and femoral neck was observed (change in z-score of 0.257 and 0.223, respectively). At the end of 2 years, there was a statistically significant difference in the change of BMD from baseline, between the NuvaRing® group and the control group.

No adverse effects on bone mass have been observed.
Other Studies
Microbiological changes were investigated in a specific safety study (n=58, 13 cycles). The majority of these findings, based on Nugent scores, were Grade I (normal) at screening, at Cycle 6 and at last assessment, and more subjects showed improvement than worsening. No subjects showed a shift from Grade I at screening to Grade III (bacterial vaginosis) at Cycle 6. The majority of vaginal colposcopy observations were normal at screening, at Cycle 6 and at last assessment. The frequency of normal to abnormal changes was low and an equal number of subjects showed abnormal to normal changes. No adverse effects on the cervix and the vagina were found.

Overall Safety
Data from all clinical studies (n=2,501) with NuvaRing® showed that it is generally safe and well-tolerated. Approximately 15% of NuvaRing®-treated subjects in all clinical studies with NuvaRing® discontinued due to an adverse event, primarily due to the ring-specific-AEs, device-related problems and vaginal discomfort. The most commonly reported AEs (5%) were vaginitis, headache, upper respiratory tract infection, leukorrhea, sinusitis, and nausea. There did not appear to be an increased incidence of these AEs with long-term NuvaRing® treatment, and there were no clinically meaningful differences in the incidence of these common AEs that could be attributed to differences in demographic characteristics age, body mass index, race, and starter/switcher status. There were no clinically relevant changes from baseline in blood chemistry, hematology, or heart rate measurement.

DETAILED PHARMACOLOGY

Animal and in vitro pharmacology
Animal pharmacology and in vitro receptor binding studies indicate that etonogestrel is a highly selective progestational agent (Table 13) with no estrogenic effects, and only residual androgenicity.

| Table 13 – Comparison of Relative Binding Affinity of Desogestrel, Etonogestrel and Progesterone for the Progesterone Receptor in Uterine Cytosol* |
|-----------------------------------|-----------------|-----------------|
|                                   | Rabbit myometrium | Human myometrium |
| desogestrel                       | 5                | 2               |
| etonogestrel                      | 111              | 113             |
| progesterone                      | 32               | 18              |

*Binding affinities were determined at 4°C using the reference standard 16α-ethyl-21-hydroxy-9-nor-pregn-4-ene-3,20-dione.

The binding affinity of etonogestrel is approximately 1/10 of 5α-dihydrotestosterone suggesting a low androgenic activity. The binding affinity for the androgen receptor in intact MCF-7 cells as displayed by etonogestrel was also significantly lower than that of other progestogens. As a result the "selectivity index" (progestogen/androgen receptor binding affinity ratio) for etonogestrel in intact MCF-7 cells is high.
TOXICOLOGY

Acute Toxicity Studies
Acute toxicity studies were conducted in rats and in mice using the oral and intraperitoneal route. Etonogestrel (ENG) was dosed orally by gavage (2,000 mg/kg) or intraperitoneally by injection (500 mg/kg). No mortalities occurred at the dose levels used. This is in agreement with published data indicating that natural and synthetic sex steroids, in general, exert low toxic activity in animals.

Chronic Toxicity Studies
The chronic toxicity studies comprised of exposure to ENG by oral administration in rats (52 weeks) and dogs (26 weeks). In rats oral dosages of up to ~70 times and in dogs up to ~160 times the anticipated average human daily dose were administered. In general, ENG induced a pattern of endocrinological changes, in particular in the genital organs and the accessory glands in rats as well as in dogs. These changes were dose-related, generally reversible and they were to be expected on the basis of the hormonal activity of ENG. Studies in rats for up to 2 years and in dogs for up to 5.8 years using ENG-containing implants also revealed no systemic or local abnormalities considered to be related to ENG or the implant. These chronic toxicity studies showed that ENG lacks intrinsic toxic properties. This is consistent with the observation that ENG is the biologically active metabolite of desogestrel (DSG).

Special toxicity studies were performed in monkeys for up to 3 months using either suppositories, vaginal rings, or oral formulations containing ENG and ethinyl estradiol (EE). The results showed that treatment with ENG and EE at intravaginal dose levels up to about 25 times and oral dose levels up to 100 times the anticipated human vaginal dose did not induce overt signs of toxicity. Long-term exposure of monkeys to a placebo ethylene vinylacetate (EVA) copolymer-containing ring was also shown to be devoid of local or systemic effects. All effects could be ascribed to the pharmacological effects of the steroids released by the ring. These observations confirm the suitability of NuvaRing® for human vaginal use.

Additional studies were performed in which several components of the combined contraceptive vaginal ring were tested via a non-vaginal route. Extracts of EVA material caused neither sensitization nor irritation upon direct contact with tissues of mice and guinea pigs in vivo. Implantation of the EVA material (with or without ENG) caused no toxic, irritation or sensitizing effects in rabbit, rat and dog. Potentially leachable components, when extracted in conformity with ISO guidelines were not cytotoxic under in vitro conditions.

The carcinogenic potential of ENG and the EVA copolymer was assessed in rats by using subdermal EVA-containing implants continuously releasing ENG, up to 40 times the human vaginal dose, for a period of 2 years. Several assessments i.e., physical observations, body weight, food consumption, hematology, macroscopic post-mortem examinations and histopathological evaluation (55 tissues including the implant site) were performed. The data showed that EVA-containing implants continuously releasing ENG lack tumorigenic properties.
Since etonogestrel is the biologically active metabolite of desogestrel and since the metabolic profiles of the two compounds are very similar supportive evidence can be obtained from carcinogenicity studies previously performed with desogestrel. In these studies desogestrel was orally administered for 81 weeks either to mice at dose levels of 2x, 20x and 200x the human desogestrel dose or to rats for 104 weeks. In neither study were neoplastic changes observed. The conclusion that desogestrel and therefore etonogestrel was non-carcinogenic can also be derived from studies previously performed in rats, dogs and monkeys using oral administration of the combination of desogestrel and ethinyl estradiol. In these studies mice and rats were treated for 80 weeks and 104 weeks, respectively at dose levels 2x, 20x and 200x the human dose. Pituitary tumor and mammary tumor induction observed in mice and rats in those studies was fully ascribed to the estrogenic component. Dogs were treated for 3 years at dose levels 2x, 10x and 25x the anticipated human dose and monkeys for 3 years at dose levels 2x, 10x and 50x the human dose. In these species only the expected non-neoplastic changes were observed and no tumorigenic effects were seen. In conclusion, chronic toxicity and tumorigenicity studies demonstrated that there is no evidence of carcinogenicity of ENG, EE or the EVA copolymer.

Reproductive Toxicity Studies
Reproductive toxicity studies were carried out in rats (Segment I and Segment II) and in rabbits (Segment II). Since pregnancy is a contraindication for the use of the vaginal ring no Segment III studies have been performed. The dose applied is approximately 500 times the anticipated average daily vaginal human dose. Treatment did not have any adverse effect on resulting litter parameters (after cessation of treatment), indicating no effect of ENG on the return of fertility after suppression with ENG. In rats and rabbits, at dosages up to ~250 times the anticipated human dose, ENG was neither embryotoxic nor teratogenic. Previous data reported using DSG support this conclusion. Thus, based on historical data on desogestrel and on recent data on ENG, it was concluded that ENG is devoid of reproductive toxicological hazards.

Mutagenicity Studies
Studies with etonogestrel also found no genotoxicity in the in vitro Ames/Salmonella reverse mutation assay, the chromosomal aberration assay in Chinese hamster ovary cells or in the in vivo mouse micronucleus test.
REFERENCES


3. van Bragt AJM, van den Heuvel MW, Doorstam DP, et al. An open-label, randomized, parallel group trial in healthy female subjects to compare the pharmacokinetics of ethinyl estradiol of NuvaRing®, to a contraceptive patch (EVRA™) and an oral contraceptive (Microgynon® 30) – NL0056998


5. Dieben THOM, Kepers M, Ramakers-van Moorsel CJA. An open-label, multicenter trial in healthy young women, to evaluate the effects of the combined contraceptive vaginal ring (Org 37681) on endometrial histology (non-comparative) and on bone mineral density compared to an intrauterine contraceptive device - NL0049743.


7. Dinger, Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC).


39. Verhoeven CHJ, Aris EMD, Ramakers-van Moosel CJA. An open-label, four-arm, randomized, group-comparative, multicenter trial to investigate continuous regimens with NuvaRing® in healthy female volunteers. Clinical Trial Report on Protocol 34230, NL0055724.


42. CHJ Verhoeven, JHM van Kuijk, JMW Smeets, CJA Ramakers – van Moorsel. An open-label, two-arm, randomized, cross-over, pharmacokinetic interaction trial with NuvaRing® and either vaginally administered anti-mycotics or tampons in healthy female volunteers - NL0039878.

43. Verhoeven CHJ, Marintcheva-Petrova MZ, Nelissen JMDT. An open-label, randomized, group-comparative, multi-center trial to evaluate the vaginal bleeding characteristics of NuvaRing® versus an oral contraceptive in healthy female volunteers – NL0052159.


45. Verhoeven CHJ, Marintcheva-Petrova MZ, Ramakers-van Moorsel CJA. A single center, open label, randomized, comparative pharmacodynamic trial with NuvaRing® versus an oral contraceptive in healthy female volunteers - NL0048713.


48. WHO Library Cataloguing – Selected practice recommendations for contraceptive use.

PART III: CONSUMER INFORMATION

Pr NUVARING®
etonogestrel/ethinyl estradiol slow release vaginal ring

CONTRACEPTIVE VAGINAL RING

This leaflet is part III of a three-part "Product Monograph" published when NuvaRing® was approved for sale in Canada, and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about NuvaRing®. Contact your doctor or pharmacist if you have any questions about the use of this product.

READ THIS PAMPHLET CAREFULLY BEFORE YOU START USING NUVARING®.

ABOUT THIS MEDICATION

What the medication is used for:
NuvaRing® (NEW-vah-ring) is a flexible contraceptive vaginal ring used to prevent pregnancy.

What it does:
Since NuvaRing® releases two different types of hormones, an estrogen and a progestin, it is called a combination hormonal contraceptive (CHC). NuvaRing® delivers 120 mcg of the progestin etonogestrel and 15 mcg/day of the estrogen, ethinyl estradiol. NuvaRing® works by releasing a steady dose of progestin and estrogen into the body. The ring is inserted into the vagina and left in place for 3 weeks in a row.

Like other combination hormonal contraceptives, NuvaRing® works in two ways:
1. By inhibiting the monthly release of an egg by the ovaries.
2. By changing the mucus produced by the cervix. This slows the movement of the sperm through the mucus into the uterus further reducing the chance of fertilization.

NuvaRing® has been shown to be highly effective in preventing pregnancy when used as prescribed.

When used according to directions, NuvaRing® is 98 to 99% effective at preventing pregnancy. This means that, for every 100 women who use NuvaRing® for a year, about one or two will become pregnant. Your chance of getting pregnant increases if NuvaRing® is not used exactly according to the directions.

Other ways to prevent pregnancy
Other methods of birth control are available to you. The following table gives reported pregnancy rates for various forms of birth control, including no birth control. The reported rates represent the number of women out of 100 who would become pregnant in one year.

<table>
<thead>
<tr>
<th>Method</th>
<th>Reported Pregnancies per 100 Women per Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combination pill</td>
<td>less than 1 to 2</td>
</tr>
<tr>
<td>Contraceptive vaginal ring</td>
<td>between 1 and 2</td>
</tr>
<tr>
<td>Intrauterine device (IUD)</td>
<td>less than 1 to 6</td>
</tr>
<tr>
<td>Condom with spermicidal foam or gel</td>
<td>1 to 6</td>
</tr>
<tr>
<td>Mini-pill</td>
<td>3 to 6</td>
</tr>
<tr>
<td>Condom</td>
<td>2 to 12</td>
</tr>
<tr>
<td>Diaphragm with spermicidal foam or gel</td>
<td>3 to 18</td>
</tr>
<tr>
<td>Spermicide</td>
<td>3 to 21</td>
</tr>
<tr>
<td>Sponge with spermicide</td>
<td>3 to 28</td>
</tr>
<tr>
<td>Cervical cap with spermicide</td>
<td>5 to 18</td>
</tr>
<tr>
<td>Periodic abstinence (rhythm), all types</td>
<td>2 to 20</td>
</tr>
<tr>
<td>No birth control</td>
<td>60 to 85</td>
</tr>
</tbody>
</table>

Pregnancy rates vary widely because people differ in how consistently and/or correctly they use each method. (This does not apply to IUDs since they are implanted in the uterus). When used as directed, users may achieve pregnancy rates in the lower ranges. Others may expect pregnancy rates more in the middle ranges.

Hormonal contraceptives (such as NuvaRing®) have important advantages over other methods of birth control. They also have certain risks that other methods do not. Your doctor is the best person to explain the consequences of any possible risks.

When it should not be used:
Hormonal contraceptives are not suitable for every woman. You should not use combination hormonal contraceptives (including NuvaRing®) if you have or have had any of the following conditions:
- blood clots in the legs, lungs, eyes, or elsewhere. For additional information, see section “RISKS OF USING HORMONAL CONTRACEPTIVES – Circulatory disorders”.
- a stroke, heart attack, chest pain (angina pectoris) or other blood circulatory disorders in the brain
- disease of the heart valves with complications
- know abnormalities of the blood clotting system that increase your risk for developing blood clots
- severe high blood pressure
- diabetes with damaged blood vessels
- very high blood cholesterol or triglyceride levels
- you smoke and are over age 35
- if you have major surgery (e.g., an operation) and your ability to move around is limited for a long period of time (see RISKS OF USING HORMONAL CONTRACEPTIVES – Circulatory disorders)
- known or suspected cancer of the breast or sex organs
- liver tumor associated with the use of the pill or other estrogen-containing products
- jaundice (yellowing of the eyes or skin), liver disease or liver tumor
• hepatitis C and are taking the combination drug regimen ombitasvir/paritaprevir/ritonavir with or without dasabuvir (see in section “INTERACTIONS WITH THIS MEDICATION”).
• cancers which are caused by or enhanced by estrogen
• eye diseases, eye lesions or defects or loss of vision
• have (had) a type of migraine called ‘migraine with aura’
• unusual vaginal bleeding that has not yet been diagnosed
• pancreatitis (inflammation of the pancreas) associated with high levels of fatty substances in your blood
• if you are pregnant or think you might be pregnant
• allergic reactions or hypersensitivity to the hormones found in the contraceptives or to any of the other components found in NuvaRing®

What the medicinal ingredient is:
etonogestrel and ethinyl estradiol

What the important nonmedicinal ingredients are:
ethylene vinylacetate copolymers and magnesium stearate. NuvaRing® does not contain any latex.

What dosage forms it comes in:
Slow-release vaginal ring – 11.4 mg etonogestrel/2.6 mg ethinyl estradiol to deliver 120 mcg etonogestrel /15 mcg ethinyl estradiol per day.

NuvaRing® is available in boxes of 1 sachet and 3 sachets.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

Cigarette smoking increases the risk of cardiovascular side effects (heart and blood vessel problems) associated with the use of hormonal contraceptives. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, NuvaRing® should not be used by women who are over 35 years of age and smoke.

NuvaRing® (as with other hormonal contraceptives) DOES NOT PROTECT against HIV infection (AIDS) and other Sexually Transmitted Infections (STIs). For protection against STIs, it is advisable to use latex or polyurethane condoms while using NuvaRing®.

BEFORE you use NuvaRing® talk to your doctor or pharmacist if:
• you are taking any other prescription or nonprescription drugs as these may interfere with the actions of NuvaRing®
• you are or will be having major surgery
• you have breast conditions
• you have a family history of breast cancer
• you have breast disorders including pain, discharge from the nipples, thickenings, or lumps
• you have a family history of circulatory disorders including blood clots, heart attacks or strokes
• you have diabetes
• you are overweight
• you have high blood pressure
• you have abnormal levels of fats in the bloodstream (high cholesterol or triglycerides)
• you are a cigarette smoker
• you have migraine headaches
• you have heart or kidney disease
• you have a history of seizures or epilepsy
• you have a history of mental depression
• you have fibroid tumors of the uterus
• you have gallbladder or pancreatic disease
• you have plans for forthcoming surgery
• you have a history of jaundice or other liver disease
• you have (or ever had) an allergic reaction while using NuvaRing®, including swelling of the face, lips, tongue, and/or throat causing difficulty in breathing or swallowing (angioedema and/or anaphylaxis)

Your doctor can advise you if you have any conditions that would pose a risk to you. The use of combination hormonal contraceptives (including NuvaRing®) should always be supervised by your doctor, with regular follow up to identify side effects associated with its use. Your visits may include a blood pressure check, a breast exam, an abdominal exam and a pelvic exam, including a Pap smear. Visit your doctor three months or sooner after the initial examination. Afterward, visit your doctor at least once a year. Use NuvaRing® only on the advice of your doctor and carefully follow all directions given to you. Use NuvaRing® exactly as prescribed or you could become pregnant.

If you see another doctor, inform him or her that you are using NuvaRing®.

NuvaRing® may not be suitable for women with conditions that make the vagina more susceptible to vaginal irritation or ulceration. Very rarely, vaginal tissue may grow over the ring, necessitating removal by a doctor. In some cases when the tissue had grown over the ring, removal was achieved by cutting the ring and not the overlying vaginal tissue.

Pregnancy is almost always more risky than using combination hormonal contraceptives. However, this risk with hormonal contraceptives can be higher if you are over 35 and you smoke.

If you and your doctor decide that, for you, the benefits of NuvaRing® outweigh the risks, you should be aware of the following:
RISKS OF USING HORMONAL CONTRACEPTIVES

Specific studies with vaginal administration of contraceptive hormones (as in NuvaRing®) are limited. The information given below was obtained in studies with oral contraceptives (the Pill) and it may also apply to NuvaRing®.

Circulatory disorders (including blood clot in legs, lungs, heart, eyes or brain)

Blood clots can develop whether or not you are using hormones for contraception. They can also happen if you are pregnant. The risk is higher in users of combined hormonal contraceptives, including NuvaRing® than in non-users, but it is not as high as the risk during pregnancy. You should talk to your doctor about the available options.

Blood clots can also occur very rarely in the blood vessels of the heart (causing a heart attack) or the brain (causing a stroke). Extremely rarely blood clots can occur in the liver, gut, kidney or eye.

Following an episode of a blood clot recovery is not always complete. Very occasionally serious permanent disabilities may occur or a blood clot may even be fatal.

If you have to undergo an operation, are bedridden for some time, or you are not supposed to walk (for example, when you have your leg or legs in plaster, or a bandage is put on to treat varicose veins), the risk of having a blood clot may be temporarily higher. In women who use contraceptive hormones, the risk may be yet higher. In such a case, ask your doctor well in advance about what you should do. Your doctor may tell you to stop using your hormonal contraception several weeks before surgery or at the time of immobilization. Your doctor will also tell you when you can start using NuvaRing® again after you are back on your feet.

If you notice possible signs of a blood clot, stop using NuvaRing® and consult your doctor immediately (see the symptoms in section ‘Side Effects and What to do About Them’).

Hormonal Contraceptives and Cancer

Breast cancer: Breast cancer has been found slightly more often in women that take the Pill than in women of the same age who do not take the Pill. It is not known whether the increased risk of breast cancer is caused by the use of a hormonal contraceptive. It may be that the women taking such a hormonal contraceptive were examined more often, so that the breast cancer is noticed earlier.

The most significant risk factors for breast cancer are increasing age and a strong history of breast cancer in the family (mother or sister). Other established risk factors include, onset of menstrual periods before age 12 years, never having children, having your first full-term pregnancy after the age of 30 years, never having breast fed a child, and daily alcohol consumption.

You should notify your doctor if you notice any breast lumps. You should also discuss breast self-examination with your doctor. A yearly breast examination by a health care professional is recommended for all women. You should also tell your doctor if a close relative has or ever had breast cancer (see Warnings & Precautions).

Cervical cancer: Some studies have found an increase of cancer of the cervix in women who use hormonal contraceptives, although this finding may be related to factors other than the use of oral contraceptives. However, there is insufficient evidence to rule out the possibility that oral contraceptives may cause such cancers.

Chronic infection with the Human Papilloma Virus (HPV) is believed to be the most important risk factor for cervical cancer. In women who use combined oral contraceptives for a long time the chance of getting cervical cancer may be slightly higher. This finding may not be caused by the Pill itself but may be related to sexual behavior and other factors.

Liver tumors: In rare cases benign liver tumors and even more rarely, malignant liver tumors have been reported in users of the Pill. These tumors may lead to internal bleeding. Contact your doctor immediately if you experience severe pain or a lump in the abdomen.

Gallbladder disease

Users of hormonal contraceptives have a greater risk of developing gallbladder disease requiring surgery within the first year of use. The risk may double after four or five years of use.

Use in pregnancy

Hormonal contraceptives should not be taken by pregnant women. There is no evidence, however, that the Pill can damage a developing child. You should check with your doctor about risks to your unborn child from any medication taken during pregnancy.

Use while breast feeding

The hormones in contraceptives are known to appear in breast milk. These hormones may decrease the flow of breast milk if hormonal contraceptives are not resumed until nursing is established. Some of the medicine may pass through the milk to the baby and could cause yellowing of the skin (jaundice) and breast enlargement.

Pregnancy after stopping NuvaRing®

A woman’s menstrual period may be delayed after stopping hormonal contraceptives. There is no evidence that the use of the contraceptive vaginal ring leads to a decrease in fertility. It is wise to delay starting a pregnancy for at least one menstrual period after stopping hormonal contraceptives, so that way the pregnancy can be more accurately dated. Your doctor can recommend a different (non-hormonal) method of contraception during this time.
Irregular Bleeding
During the use of NuvaRing®, in some women, unexpected vaginal bleeding (spotting or breakthrough bleeding) between periods may occur. You may need to use sanitary protection, but continue to use the ring as normal. If the irregular bleeding continues, becomes heavy or starts again, tell your doctor.

Ring Disconnection/Breakage
Very rarely, NuvaRing® may break. A broken ring is unlikely to cause an overdose because the ring will not release a higher amount of contraceptive hormones. Vaginal injury associated with ring breakage has been reported. If NuvaRing® breaks, expulsion is more likely to occur (see ‘What Should I do if NuvaRing® disconnects?’). Therefore, if you notice that your NuvaRing® has broken, discard that ring and replace it with a new ring as soon as possible.

Risk to the Partner
The effects of hormones released by NuvaRing® on male partners during sexual intercourse have not been studied.

During market use, partner penis discomfort (e.g., pain, rash, bruises and abrasions), has been reported.

INTERACTIONS WITH THIS MEDICATION

Certain drugs may interact with hormonal contraceptives (including NuvaRing®) and prevent NuvaRing® from working properly. This can make hormonal contraceptives less effective in preventing pregnancy or cause unexpected bleeding (spotting or breakthrough bleeding). Hormonal contraceptives may also interfere with the working of other drugs.

Please inform your doctor or pharmacist if you are taking or have recently taken any other drugs or herbal products, even those without a prescription. Also, tell any other doctor or dentist who prescribes another drug (or the dispensing pharmacist) that you use NuvaRing®.

Drugs that may interact with NuvaRing® include:
- drugs used for the treatment of epilepsy (e.g., lamotrigine, primidone, phenytoin, barbiturates (e.g. phenobarbital), carbamazepine, oxcarbazepine, topiramate, felbamate);
- drugs used for the treatment of tuberculosis (e.g., rifampicin, rifabutin)
- drugs used for the treatment of HIV infections or AIDS (e.g., ritonavir, nelfinavir, nevirapine, efavirenz), and Hepatitis C Virus infections (e.g., boceprevir, telaprevir)
- antibiotics (e.g., nitrofurantoin) for infectious diseases
- antifungals (e.g., griseofulvin)
- anti-coagulants (blood thinners)
- the herbal remedy, St. John’s wort
- antihypertensive drugs (for high blood pressure)
- drugs used for high blood pressure in the blood vessels of the lungs (bosentan);
- antidiabetic drugs and insulin (for diabetes)
- prednisone
- sedatives and hypnotics (e.g., barbiturates, glutethimide, meprobamate)
- antidepressants (e.g., clomipramine)
- antacids
- other drugs such as phenylbutazone, antihistamines, analgesics, anti-migraine preparations
- cholesterol-lowering drugs (e.g., clofibrate)
- cyclosporine
- some nutritional supplements (eg. Vitamin E and Vitamin B12)

This is not a complete list of possible drug interactions with NuvaRing®.

If you are taking medicines or herbal products that might make NuvaRing® less effective, a barrier contraceptive method should also be used. Since the effect of another medicine on NuvaRing® may last up to 28 days after stopping the medicine, it is necessary to use the additional barrier contraceptive method for that long.

NuvaRing® may also interfere with the working of other drugs, causing either an increase in effect (e.g., cyclosporin) or a decrease in effect (e.g., lamotrigine).

Do not use NuvaRing® if you have Hepatitis C and are being treated with ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. Using these drugs at the same time as NuvaRing® can cause problems with your liver, such as an increase in the ALT liver enzyme. You can usually start using NuvaRing® about 2 weeks after finishing treatment with these combination drugs used for Hepatitis C, but always consult with your doctor or pharmacist (see in section “ABOUT THIS MEDICATION-When it should not be used”).

Talk to your doctor for more information about drug interactions.

Can I use tampons when using NuvaRing®?

The blood levels of the hormones released by NuvaRing® were not changed when women used tampons along with NuvaRing®. It is unknown how this affects the safety and the pregnancy protection of NuvaRing®. Insert NuvaRing® before inserting a tampon. You should pay particular attention when removing a tampon to be sure that the ring is not accidentally pulled out. If this should occur, simply rinse the ring in cool to lukewarm (not hot) water and immediately reinsert it.

Regularly check that NuvaRing® is in your vagina to ensure that you are protected from pregnancy.
Can I use vaginal medications?
The blood levels of the hormones released by NuvaRing® were not changed when women used vaginal, water-based spermicides (nonoxynol or N-9 products) along with NuvaRing®.

The blood levels of the hormones released by NuvaRing® were increased when women used either an oil-based or water-based vaginal medication (miconazole nitrate) for a yeast infection while NuvaRing® was in place. Therefore, this may also happen with other yeast infection medications. The clinical relevance of this increase is unknown. It is unknown how long-term use of spermicide or yeast infection medication with NuvaRing® affects the safety and the pregnancy protection of NuvaRing®.

Ring breakage has occurred when also using a vaginal product such as a lubricant or treatment for infection (see also Warnings and Precautions/Ring Disconnection/Breakage).

PROPER USE OF THIS MEDICATION

If you decide to use hormonal contraceptives
If you and your doctor decide that, for you, the benefits of hormonal contraceptives outweigh the risks, you should be aware of the following:

1. Your doctor will advise you of the appropriate time to start the use of hormonal contraceptives after childbirth, miscarriage, or therapeutic abortion.
2. There is no need to stop taking hormonal contraceptives for a rest period.

If you want more information about contraceptive vaginal rings, ask your doctor or pharmacist.

Usual dose:
NuvaRing® is designed to be a once-a-month contraceptive regimen. The ring has to be inserted in your vagina.

Regularly check that NuvaRing® is in your vagina (for example, before and after intercourse) to ensure that you are protected from pregnancy.

After the ring is inserted, it releases a continuous low dose of hormones into your body. The ring stays in place for 3 weeks and then is removed for a one week ring free period. It is not necessary or recommended to remove NuvaRing® during intercourse.

READ THESE DIRECTIONS CAREFULLY
For the best protection from pregnancy, use NuvaRing® exactly as directed. Insert one NuvaRing® in the vagina and keep it in place for three weeks in a row. Remove it for a one-week break and then insert a new ring. During the one-week break, you will usually have your menstrual period. Your healthcare provider should examine you at least once a year.

Do not use NuvaRing® for a condition for which it was not prescribed. Do not give NuvaRing® to anyone else who may want to use it.

You should not use a NuvaRing® if it was dispensed to you more than 4 months before or if the expiry date has passed. The dispensing date and expiry date are both shown on the carton and sachet.

Do not use the ring if you notice a color change in the ring or any visible signs of deterioration.

While using NuvaRing®, you should not use certain female barrier contraceptive methods such as vaginal diaphragm, cervical cap or female condom as your back-up method of birth control because NuvaRing® may interfere with the correct placement and position of a diaphragm, cervical cap or female condom.

When should I start NuvaRing®?
Follow the instructions in one of the sections below to find out when to start using NuvaRing®:

If you did not use a hormonal contraceptive in the preceding cycle
Insert NuvaRing® within the first five days of your cycle (i.e., Day 1-5 of the menstrual bleeding). Make sure you also use an extra method of birth control (barrier method), such as male condoms or spermicides during the first seven days of NuvaRing® use in the first cycle.

If you are switching from a combined hormonal contraceptive containing both progestin and estrogen
Switch from your previous combined hormonal contraceptive on any day, but at the latest on the day you would have started a new cycle, by inserting NuvaRing®. If you have been using your hormonal contraceptive method consistently and correctly, no extra birth control method should be needed.

If you are switching from a progestin-only contraceptive (mini-pill, implant, injection, or from a progestagen-releasing intrauterine system [IUS])
- When switching from a mini-pill, you can stop using the pill on any day of the month and switch to NuvaRing®. Insert NuvaRing® on the day immediately after your last pill.
- When switching from an implant, progestin-containing IUS or injectable contraceptive, start using NuvaRing® on the same day you have your implant or IUS removed or on the day your next injection is due.

When you are switching from a progestin-only contraceptive, use an extra method of birth control, such as a male condom and/or spermicide, for the first seven days after inserting NuvaRing®.
“Use after pregnancy, miscarriage or abortion”
Talk to your doctor about using NuvaRing® following an abortion, miscarriage or childbirth or under any other circumstances that are not listed in this Consumer Information.

How do I insert NuvaRing®?
1. After washing and drying your hands, remove NuvaRing® from its foil pouch. Keep the foil pouch for proper disposal of the ring after use. Choose a position that is most comfortable for you (e.g., Figure 1).

Figure 1: Positions for NuvaRing® insertion

2. Press the sides of NuvaRing® together between your thumb and index finger (Figure 2) and gently push the folded ring into your vagina (Figure 3). The exact position of NuvaRing® in the vagina is not important for it to work.

Figures 2: Holding NuvaRing® and pressing the sides together.

Figure 3: Inserting NuvaRing®.
Although some women may be aware of NuvaRing® in the vagina, most women do not feel it once it is in place. If you feel discomfort, change the position of the NuvaRing® (i.e., use your finger to gently push NuvaRing® further into your vagina) until it is comfortable. There is no danger of NuvaRing® being pushed too far up in the vagina or getting lost.

3. Once inserted, keep NuvaRing® in place for three weeks in a row.

How do I remove NuvaRing®?
1. Remove the ring three weeks after insertion on the same day of the week as it was inserted, at about the same time. For example, when NuvaRing® is inserted on a Sunday at about 10:00 PM, the ring should be removed on the Sunday three weeks later at about 10:00 PM.
Remove NuvaRing® by hooking the index finger under the forward rim or by holding the rim between the index and middle finger and pulling it out (Figure 4).

![Figure 4](image)

2. Place the used ring in the reclosable foil pouch and properly dispose of it in a waste receptacle, out of the reach of children and pets. Do not throw it in the toilet.

If you are unable to remove NuvaRing®, please contact your healthcare provider.

Your menstrual period will usually start two to three days after the ring is removed and may not have finished before the next ring is inserted. To continue to have pregnancy protection, you must insert the new ring one week after the last one was removed, even if your menstrual period has not stopped.

When do I insert a new ring?
After a one-week ring-free break, insert a new ring on the same day, at the same time of the week as it was removed in the last cycle. For example, if NuvaRing® was removed on a Sunday at about 10:00 PM, after the one-week break you should insert a new ring on a Sunday at about 10:00 PM.

If NuvaRing® is in your vagina too long:
If NuvaRing® has been left in your vagina for an extra week or less (up to four weeks total), you will remain protected. Remove NuvaRing® and insert a new ring after a one-week ring-free break.

If NuvaRing® has been left in place for more than four weeks total, there is a possibility that you could become pregnant. You must rule out pregnancy before inserting a new NuvaRing®. You must use an extra method of birth control, such as male condom and/or spermicide, until the new NuvaRing® has been in place for seven days in a row.

What should I do if NuvaRing® disconnects?
On rare occasions, NuvaRing® may disconnect at the weld joint during use. Since the ring’s core is solid its contents will remain intact and release of hormones will not be significantly affected. Vaginal injury associated with ring breakage has been reported. If NuvaRing® does disconnect, expulsion (slipping out) is likely to occur (see “If NuvaRing® slips out”). If you discover the ring has disconnected you should discard the ring and replace it with a new ring.

How to change the NuvaRing® start day to another day of the week
If you wish to change the day on which you start a new NuvaRing® cycle to another day of the week, complete the current cycle, removing NuvaRing® on the same day of the week as the one on which you started. During the ring-free period, a new start day may be selected by inserting the new NuvaRing® on the first occurrence of the desired day. This will be your new Day 1. In no case should there be more than 7 consecutive ring-free days.

The shorter the ring-free interval, the higher the risk that you do not have a period from your previous cycle. However, spotting or bleeding may occur during the use of the next ring. This practice is for a one-time only change and should not to be used as a standard dosing regimen, as there are no long-term safety data available on the continuous use of NuvaRing®.

If you miss a menstrual period:
You must check to be sure that you are not pregnant if:

1. you miss a period and NuvaRing® was out of the vagina for more than three hours during the three weeks of ring use
2. you miss a period and you had waited longer than one week to insert a new ring
3. you have followed the instructions and you miss two periods in a row
4. you have left NuvaRing® in place for longer than four weeks

Overdose:
Overdosage of combination hormonal contraceptives may cause nausea, vomiting, vaginal bleeding, or other menstrual irregularities. Given the nature and design of NuvaRing® it is unlikely that overdosage will occur. If NuvaRing® is broken, it does not release a higher dose of hormones. There are no antidotes and further treatment should be symptomatic.

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:
If NuvaRing® slips out:
NuvaRing® can slip out of the vagina if it has not been inserted properly, or while removing a tampon, during intercourse or straining during a bowel movement. Therefore, it is a good habit to regularly check whether the ring is still in your vagina (for example, before and after intercourse).

If NuvaRing® was out of the vagina for:
- **less than three hours**, you should still be protected from pregnancy. NuvaRing® can be rinsed with cool to lukewarm (not hot) water and should be re-inserted as soon as possible, and at the latest within three hours of expulsion (slipping out). If you have lost NuvaRing®, you must insert a new
important: please read

nuvaring® and use it on the same schedule as you would have used the lost ring.

- **more than three hours during the 1st or 2nd week**, you may not be adequately protected from pregnancy. you should rinse the ring with cool to lukewarm (not hot) water. re-insert the ring as soon as you remember and use an extra method of birth control, such as male condoms or spermicides, until the nuvaring® has been in place continuously for **seven days in a row**.

- **more than 3 hours during the 3rd week** contraceptive efficacy may be reduced. throw the ring away and choose one of the following two options:

  1. insert a new ring immediately. note: inserting a new ring will start the next three-week use period. you may not experience a period from your previous cycle. however, breakthrough spotting or bleeding may occur.

  2. have your period and insert a new ring no later than 7 days from the time the previous ring was removed or expelled. note: this option should only be chosen if the ring was used continuously for the preceding 7 days.

in addition, a barrier method such as a male condom and/or spermicides must be used until the new ring has been used continuously for seven days.

if nuvaring® was out of the vagina for:

- **unknown amount of time**, you may not be protected from pregnancy. perform a pregnancy test and consult your doctor prior to inserting a new ring.

women with conditions affecting the vagina, such as a prolapsed uterus, may be more likely to have nuvaring®-slip out of the vagina.

if the ring-free period is extended

if the ring-free interval has been extended beyond one week, the possibility of pregnancy should be considered and an extra method of birth control, such as male condoms or spermicide must be used until nuvaring® has been used continuously for seven days.

contact your doctor immediately. the longer the ring-free interval, the higher the risk that you have become pregnant

how well tolerated is nuvaring®?

more than 2,100 women were questioned in a survey of their experiences using nuvaring® for several months.

nearly all of the women found nuvaring® easy to insert (96%) and remove (98%). most women did not feel nuvaring® once it was in place and 83% of women said they never or rarely felt nuvaring® during intercourse. similarly, 68% of women said their partners never or rarely felt the ring during intercourse, and 91% reported that their partner did not mind them using the ring.

of the 1499 women who completed one year treatment (13 cycles) with nuvaring®, 96% reported they were satisfied with nuvaring®, and 97% reported they would recommend nuvaring® to others. 85% of all women surveyed were satisfied with the use of nuvaring® and 90% would recommend this method to others.

non-contraceptive benefits of hormonal contraceptives

several health advantages have been linked to the use of hormonal contraceptives.

- reduction in the incidence of cancer of the uterus and ovaries.
- reduction in the likelihood of developing benign (non-cancerous) breast disease and ovarian cysts.
- less menstrual blood loss and more regular cycles. the risk of developing iron-deficiency anemia is thus reduced.
- there may be a decrease in painful menstruation and premenstrual syndrome (pms).
- acne, excessive hair growth and male-hormone-related disorders also may be improved.
- ectopic (tubal) pregnancy may occur less frequently.
- acute pelvic inflammatory disease may occur less frequently.

this may also be the case for nuvaring® but this has not been confirmed.

side effects and what to do about them

combination hormonal contraceptives (including nuvaring®) are not suitable for every woman.

in a small number of women, serious side effects may occur. the most serious side effects of combined hormonal contraceptives include:

- circulatory disorders (including blood clots in legs, lungs, heart, eyes, or brain)
- breast cancer
- gall bladder disease or liver tumors
- endometriosis

contact your doctor as soon as possible if you notice any changes in your own health, especially involving any of the items mentioned in this leaflet (see also warnings and precautions). do not forget about the items related to your immediate family.

with all hormonal contraceptives, for the first few months, you can have irregular vaginal bleeding (spotting or breakthrough bleeding) between your periods. you may need to use sanitary protection, but continue to use nuvaring® as normal. irregular vaginal bleeding usually stops once your body has adjusted (usually after about 3 cycles). if it continues, becomes heavy or starts again, tell your doctor.
Users of NuvaRing® have reported the following side effects:
- headache;
- vaginal discomfort (e.g., vaginal secretion, infection of the vagina);
- weight increase;
- nausea;
- breast pain;
- mood changes (e.g., depressive moods and emotional lability);
- painful menstruation;
- acne;
- decreased libido;
- abdominal pain;
- migraine;
- expulsion of the ring, problems during intercourse and feeling of the ring.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In rare cases the following undesirable effects were reported during use of NuvaRing®:
- itching in the genital area;
- rash;
- allergic reaction;
- inflammation of the cervix;
- urinary tract infection;
- bladder infection;
- dizziness;
- anxiety;
- diarrhea and vomiting;
- breast discharge;
- back pain;
- enlarged abdomen;
- fatigue;
- vaginal injury associated with broken rings;
- penis discomfort of the partner (such as irritation, rash, itching).

### SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Remove the ring and call your doctor or pharmacist</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td>Uncommon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sharp pain in chest, coughing</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>sudden severe or worsening headache or vomitting, dizziness or fainting, disturbance of vision or speech, or weakness or numbness in an arm or leg/stroke</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>sudden partial or complete loss of vision or double vision/ blood clot in the eye</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>severe pain or lump in the abdomen/ liver tumor</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>severe depression</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>yellowing of the skin/ jaundice</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>unusual swelling of the extremities</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>breast lumps, breast tumors, breast cancer</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>urinary urgency, frequency, burning and/or painful urination, and cannot locate the ring in the vagina/ inadvertent insertion of NuvaRing® into the urinary bladder</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Hives, swelling of the face, lips, tongue and/or throat causing difficulty in breathing or swallowing (angioedema and/or anaphylaxis)/ hypersensitivity</td>
<td>√</td>
<td></td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. For any unexpected effects while taking NuvaRing®, contact your doctor or pharmacist.

### HOW TO STORE IT

Store NuvaRing® at room temperature (2–30 °C). Protect from light.

Do not use a NuvaRing® if it was dispensed to you more than 4 months ago. The dispensing date is shown on the box.

Do not use NuvaRing® after the expiry date which is shown on the box.

Do not use NuvaRing® if you notice a color change in the ring or any visible signs of deterioration.

Keep out of reach of children and pets.
If you discover that a child has been exposed to the hormones from NuvaRing®, ask your doctor for advice.

**Reporting Side Effects**

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

**3 ways to report:**
- Online at MedEffect;  
  (hc-sc.gc.ca/dhp-mps/medeff/index-eng.php)
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
  - Fax to 1-866-678-6789 (toll-free), or
  - Mail to: Canada Vigilance Program  
    Health Canada, Postal Locator 1908C  
    Ottawa, ON K1A 0K9

Postage paid labels and the Consumer Side Effect Reporting Form are available at MedEffect.

**NOTE:** Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

**MORE INFORMATION**

**If you want more information about Nuvaring®:**
- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Consumer Information by visiting the Health Canada website (http://hc-sc.gc.ca/index-eng.php) or Merck Canada website www.merck.ca or by calling Merck Canada at 1-800-567-2594

This leaflet was prepared by Merck Canada Inc.

Last revised: September 20, 2018

* Merck Sharp & Dohme B.V. Used under license.

© 2011, 2018 Merck Canada Inc. All rights reserved.